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SUMMARY 
Birt-Hogg-Dubé (BHD) syndrome is a rare autosomal dominant condition caused by 
mutations in the FLCN gene and characterised by benign hair follicle tumours, 
pneumothorax and renal cancer. Folliculin (FLCN), the protein product of FLCN, is a poorly 
characterised tumour suppressor, currently linked to multiple cellular pathways. Autophagy is 
an evolutionarily conserved biological process that maintains cellular homeostasis by 
removing damaged organelles and macromolecules. Although the autophagy kinase, ULK1, 
is known to initiate autophagy, the underlying mechanisms are still being unravelled and new 
ULK1 substrates are being identified. In this study, FLCN is identified as a new ULK1 
substrate that interacts with the autophagy machinery via GABARAP. FLCN/GABARAP 
interaction is shown to be modulated by the presence of FNIP1 and FNIP2, as well as ULK1-
directed phosphorylation of FLCN. Furthermore, loss of FLCN impairs autophagy while re-
expression rescues autophagy. FLCN was found to interact with several Rab small G 
proteins linked to autophagy, implicating FLCN in vesicular trafficking. 
Upon generation of FNIP1/2 knockdown cell lines it was revealed that FNIP2 is 
possibly involved in the transcriptional regulation of FLCN and is involved in FNIP1’s 
translation and/or stability. Moreover, FNIP1 could be involved in regulation of FNIP2’s 
transcription via a negative feedback mechanism. FNIP proteins were further implicated in 
autophagy when FNIP1 and FNIP2 gene expression were found to be significantly increased 
upon starvation in HK2 cells. Additionally, p62 and GABARAP protein levels demonstrated a 
significant increase in FNIP2 knockdown cell lines suggestive of impaired autophagy. 
This work substantially contributes to our understanding of FLCN by linking it directly 
to autophagy. Furthermore, FLCN and the FNIPs are shown to be involved in multiple 
protein interactions which could mean that FLCN and its interacting partners might have a 
more universal housekeeping role, which when lost leads to cancer. 
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1 Chapter 1: General Introduction 
 
1.1 Birt-Hogg-Dubé Syndrome 
Birt-Hogg-Dubé (BHD) syndrome (OMIM 135150) is a rare, autosomal 
dominant, hamartoma disorder which is characterized by benign tumours of the hair 
follicle (fibrofolliculomas), lung cysts and pneumothorax (collapsed lung), and renal 
neoplasia. BHD was first described in 1977 by three Canadian doctors – Birt, Hogg 
and Dubé (Birt et al. 1977). The syndrome had also been identified 1975 by 
Hornstein and Knickenberg (Hornstein & Knickenberg 1975) and there has been 
suggestion of renaming the disease to Hornstein-Birt-Hogg-Dubé, however due to 
confusion this name was never used. 
A genome-wide linkage analysis using polymorphic microsatellite markers on 
a large Swedish family in 2001 mapped the BHD-associated locus to chromosome 
17p12-q11.2. (Khoo et al. 2001). Subsequently in 2002 a novel gene BHD, which 
encodes a 64 KDa protein called folliculin (FLCN), was reported to be inactivated in 
individuals with BHD syndrome (Nickerson et al. 2002).  
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1.2 Clinical Manifestation  
 Skin 1.2.1
Usually after the age of 20, skin lesions start to appear in most of the BHD 
patients, where these skin lesions are termed Fibrofolliculomas (Menko et al. 2009). 
Fibrofolliculomas are benign hair follicle tumours appearing on skin as whitish 
papules. These lesions are mainly developed on the face; they can also be 
commonly found on the neck, upper torso and ears (Menko et al. 2009). 
Trichodiscomas (skin-coloured tumours occurring on the upper body), skin tags 
(acrochordon-like lesions) and fibrofolliculomas were previously considered as 
distinct hallmarks of BHD syndrome however Fujita et al. 1981, De la Torre et al.  
1999 and Misago et al. 2009 showed that these benign tumours were merely a 
morphological  spectrum of the same histological entity (Fujita et al. 1981)(De la 
Torre et al. 1999)(Misago et al. 2009).  
In 2013, Vernooij et al. suggested that fibrofolliculomas arise from sebaceous 
glands rather than hair follicles. They found that most of the epithelial strands making 
up the lesion are a continuation of the sebaceous glands. This could possibly be as a 
result of ciliary dysfunction in either the sebaceous gland progenitor or stem cells, 
which in turn could explain the formation of skin lesions around the areas rich in 
sebaceous glands such as the nose and perinasal skin (Vernooij et al. 2013).   
In 2010, Cocciolone et al. suggested a connection between desmoplastic 
melanoma and BHD in a 58 year old patient as a result of mammalian target of 
rapamycin (mTOR) up-regulation. There are 6 other cases of melanoma reported in 
patients with a BHD mutation; although quite possibly the event could be 
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coincidental and a direct link cannot be confirmed (Cocciolone et al. 2010)(Leter et 
al. 2008).  
The range of skin manifestation in BHD patients varies. Some patients do not 
develop any skin abnormalities at all whereas the number of fibrofolliculomas in 
other patients can differ from under 10 to over 100 (Toro et al. 1999).  
Some skin abnormalities seen in BHD patients are quite similar to a few other 
genetic disorders shown in Table 1.1.  
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Table 1.1. Hair follicle tumour syndromes similar to BHD
 
Disease 
 
Gene 
 
Lesion 
 
Pathogenesis Mechanism 
 
Inheritance 
Birt Hogg Dube Syndrome FLCN Fibrofolliculoma Not fully understood 
Possibly mTOR dysregulation/ 
ciliary dysfunction/ autophagic 
and apoptotic dysregulation 
Autosomal dominant/ new mutation 
Tuberous Sclerosis  
Complex 
TSC Angiofibroma mTORC1 up-regulation/ciliary 
dysfunction 
Autosomal dominant/ new mutation 
Cowden Disease PTEN Trichilemmoma PI3K-AKT / mTOR up-regulation Autosomal dominant 
Muir-Torre Syndrome MLH1/MSH2 Sebaceous adenomas 
Sebaceous epitheliomas 
Sebaceous carcinomas 
DNA mismatch repair Autosomal dominant 
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 Lung 1.2.2
The earliest symptoms reported in BHD patients to date are lung problems, 
where three independent studies have reported early incidents of pneumothoraces in 
three different patients at the age of seven, fourteen and sixteen (Bessis et al. 
2006)(Gunji et al. 2007)(Johannesma et al. 2014). Whereas in 2013 Kunogi Okura et 
al. presented a case of 73 year old woman with her first spontaneous pneumothorax 
occurring at the age of 73 (Kunogi Okura et al. 2013). These extreme findings can 
suggest that the age of onset for spontaneous pneumothorax in BHD patients is 
quite variable.  
Toro et al. in a study of 152 patients from 49 families first described the 
presence of pulmonary cysts in BHD patients (Toro et al. 1999). Most of BHD 
patients are likely to develop pulmonary cysts and are susceptible to recurrent 
spontaneous pneumothorax. The study of 50 BHD families showed 88% of the 
families developed pulmonary cysts and 53% of the families had a history of 
pneumothorax (Toro et al. 2007). In another study, Toro et al. reported a 93% 
pulmonary cyst presence in BHD patients (Toro et al. 2008). The numbers of 
pulmonary cysts have been postulated by Zbar et al. to correlate with episodes of 
spontaneous pneumothoraces (Zbar et al. 2002).  In the Toro et al. study of 89 
families with BHD, patients with pulmonary cysts were found to have a 24 % risk for 
spontaneous pneumothorax. They also found that after having one episode of 
spontaneous pneumothorax, recurrence of the episode becomes more common 
(Toro et al. 2007). An independent study of 20 BHD families showed 11% of affected 
BHD patients had a history of pneumothorax however pulmonary CT screening for 
the presence of pulmonary cysts  was not carried in this study (Leter et al. 2008).  
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According to Toro et al. and Tobino et al., although BHD patients usually have 
multiple pulmonary cysts, lung anatomy and histology mostly appears to be normal 
and generally lung function is not affected (Toro et al. 2007)(Tobino et al. 2011). 
In 2011, Tobino et al. carried out a differential study between 
Lymphangioleiomyomatosis (LAM) and BHD pulmonary cysts in 12 patients and 
concluded that the distinct characterisation of BHD pulmonary cyst is their 
predominant distribution towards the medial and lower zone. They also observed 
that the number of cysts present in different BHD patients varies between 29 to 407, 
and the shape of the cyst was generally irregular (Tobino et al. 2011). Another study 
of 17 BHD patients also found that multiple lung cysts are mainly (93%) present in 
the lower lungs and that the cysts were different in size and shape (Agarwal et al. 
2011). 
A more recent study used histopathologic examination of the cysts of 11 BHD 
patients and found that the cysts are lined with epithelial cells or pneumocyte-like 
cuboidal cells. They also found that some of the cysts had alveolus-like structures 
within them or as they called it "alveoli within an alveolus" pattern. The cysts were 
stained for phospho-S6 which proved to be positive, indicating active mTOR pathway 
in theses cysts (Furuya et al. 2012). 
The analysis of 229 lung cysts from 50 BHD patients by Kumasaka et al. and 
comparing them with the analysis of 117 lung cysts from 34 primary spontaneous 
pneumothorax (PSP) patients, has provided a better characterisation of pulmonary 
cysts in BHD patients. They found that the BHD cysts are usually surrounded by 
normal alveolar walls; they could have intracystic septa and are found in both 
subpleural and intrapulmonary areas. They postulated that BHD cysts grow in size 
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possibly by expanding at the alveolar-septal junction where the alveolar walls 
disappear. FLCN loss has also been suggested as the cause of weaker alveoli walls 
which makes the lungs more vulnerable to mechanical stress which in turn causes 
cyst formation (Kumasaka et al. 2014). 
Overall the common presence of pulmonary cyst in BHD patients could be 
indicative of important role of FLCN in normal lung physiology.  
 
 Kidney 1.2.3
One of the most severe consequences of BHD is the predisposition of the 
BHD patients to develop renal cell carcinoma (RCC) (Toro et al. 1999). 
In a study of 115 BHD patients from 35 families by Houweling et al. 12% (14) 
of the patients developed renal cell carcinoma and 5 out of these 14 individuals had 
metastatic tumours (Houweling et al. 2011). However in a larger study Pavlovich et 
al. examined 124 individuals with BHD and found 34 (27%) with renal tumours 
(Pavlovich et al. 2005). Toro et al. also studied 89 BHD patients from 50 families and 
found 30 individuals (34%) had developed renal cell carcinoma (Toro et al. 2008). In 
a more recent study, Benusiglio et al. examined 124 BHD patients from 72 families 
and found 33 of the patients (27%) with a history of renal tumours (Benusiglio, 
Giraud, et al. 2014). It is important to take into account that these differences in 
prevalence of renal cell carcinoma in BHD patient could be due to the number of the 
population studied and also the way these patients were recruited; for example in 
Houweling et al. study most of the patients were recruited through dermatology 
clinics whereas in Benusiglio et al. study patients were recruited through National 
Hereditary Kidney Cancer Centre in Paris and the Molecular Genetics Laboratory at 
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the Edouard Herriot University Hospital in Lyon. Therefore it is difficult to accurately 
predict the percentage risk of developing kidney cancer in BHD patients. 
Interestingly, two independent studies have found somatic mutation of FLCN 
in sporadic renal cell carcinoma (Khoo et al. 2003)(Gad et al. 2007). Khoo et al. only 
found one FLCN mutation in 39 studied samples and Gad et al. found six FLCN 
mutation in the 92 studied samples. Moreover, a recent case study of a 74 year old 
man who had no family history of cancer and presented with benign oncocytoma 
transitioning to regions of high-grade carcinoma; showed that heterozygous loss of 
FLCN was partly the cause of this transition. In the high-grade carcinoma region as 
well as heterozygous loss of FLCN other genes were shown to be dysregulated such 
as vascular endothelial growth factor A, metalloproteinases matrix metallopeptidase 
9 and matrix metallopeptidase 12 which could contribute to angiogenesis and 
invasiveness (Sirintrapun et al. 2014).  
BHD-associated renal tumours have proven to be of diverse histological 
nature. One of the earliest histological analysis, involving 130 solid renal tumours of 
30 BHD patients from 19 families, found most of the tumours to be hybrid oncocytic 
neoplasms and chromophobe renal cell carcinoma (65 of 130, 50%) or chromophobe 
renal cell carcinomas (44 of 130, 34%). 12 of the 130 tumours were diagnosed to be 
clear cell (9%) and 7 of the 130 tumours were diagnosed to be oncocytoma (5%) and 
only 2% of the tumours (2 of the 130) were papillary (Pavlovich et al. 2002). However 
the Houweling et al. study of 14 BHD patients with renal cell carcinoma from 35 
families showed that most of the renal tumours were of chromophobe and clear cell 
nature, also most of the tumour cells had moderately enlarged nuclei with sharp cell 
borders and eosinophilic cytoplasm which meant that they could be intermediate 
between clear cell and chromophobe carcinoma. Five of these patients developed 
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metastatic disease (Houweling et al. 2011). In a more recent study of 33 BHD 
patients 23 of them (70%) had tumours with either chromophobe or hybrid 
chromophobe-oncocytoma characteristics; and only three (9%) had clear cell 
carcinoma. The rest of them either had carcinoma of papillary or the histology of the 
renal tumour could not be determined. Four of these BHD patients developed 
metastatic disease (Benusiglio, Giraud, et al. 2014).   
Interestingly there are two independent reports of BHD patients who have 
developed renal angiomyolipomas. Renal angiomyolipomas are distinct 
characteristics of TSC and it is not usually seen in BHD patients. However 
involvement of both TSC and FLCN in mTOR Complex 1 (mTORC1) pathway could 
be the reason behind the development of renal angiomyolipomas in BHD patients 
(Byrne et al. 2012)(Tobino & Seyama 2012).  
Although originally, because of the high percentage of chromophobe tumours 
in the Pavlovich et al. study, it was thought that the renal tumours in BHD patient 
arise from the distal nephron (Pavlovich et al. 2002); it was later demonstrated by 
two independent studies that the site of origin for BHD renal tumours is the proximal 
tubules (Chen et al. 2008)(Hudon et al. 2010).  
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 Other clinical manifestations associated with BHD 1.2.4
To date the only confirmed manifestations associated with BHD syndrome 
are: Fibrofolliculomas, pulmonary cysts, spontaneous pneumothorax and renal cell 
carcinoma, however different studies have reported other clinical manifestations 
linked to BHD syndrome. 
1.2.4.1 Colorectal polyps and colorectal cancer  
Hornstein et al. and Birt et al. were the first groups to describe BHD and they 
suggested that there is an association between BHD syndrome and colorectal 
cancer (Hornstein 1976) (Birt et al. 1977). Subsequently two independent studies 
also proposed that there is a link between BHD syndrome and colorectal cancer 
(Schachtschabel et al. 1996) (Schulz & Hartschuh 1999). Conversely, in a large 
study of 33 BHD families with 98 affected members Zbar et al. could not find any 
correlation between polyps or colorectal cancer and BHD (Zbar et al. 2002). 
Nonetheless, Khoo et al. found six affected members of a BHD family presented with 
colorectal polyps and colorectal cancer, however they discuss that environmental or 
additional genetic factors could be contributing factors in certain families (Khoo et al. 
2002). More recently in a study of 149 BHD patients from 51 families Nahorski et al. 
found 10 of these patients (6.7%) had colorectal polyps or cancer and all of these 
patients had mutation in exon 11 of FLCN (c.1285dupC), which could be suggestive 
of a possible genotype-phenotype correlation (Nahorski et al. 2010). However for 
any study of this nature to reach conclusive and statistical significance, a much 
larger cohort is needed. 
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1.2.4.2 Thyroid nodules and cancer  
A long term study of 22 BHD patient from 10 families over the course of five 
years by Kluger et al., found that strikingly 13 of these patients (65%) had developed 
thyroid nodules or cysts whereas no colorectal carcinoma was detected. Also they 
could not detect any genotype-phenotype correlation (Kluger et al. 2010). Although 
this is a great study in characterising the clinical manifestation of the BHD syndrome, 
since they did not use a control group for comparison the significance of their 
findings is quite questionable. In a more genetically focused study Benhammou et al. 
also found “6 of 15 patients with thyroid findings”. Three of these patients had 
hypothyroidism, one of them had thyroid nodule and one of them had total 
thyroidectomy due to thyroid cancer. Although this was not a clinical study it provides 
further BHD link to thyroid abnormalities (Benhammou et al. 2011). More recently a 
case study reported a 72 year old man with BHD who was presented with right 
thyroid nodule. Further investigation revealed that the lesion was thyroid cancer. 
Interestingly they found loss of heterozygosity of FLCN in the tumour tissue but not 
the surrounding normal tissue (Benusiglio et al. 2014). Another case study of a 45 
year old woman also reported the patient with thyroid cancer. However this patient 
was diagnosed with BHD after the thyroid cancer and the link between BHD and 
thyroid cancer was not investigated in this study (Yamada et al. 2015). Interestingly a 
case study of a 57 year old woman with metastatic anaplastic thyroid cancer 
demonstrated somatic mutation in TSC2, FLCN and TP53 genes. Initially the tumour 
was successfully treated with everolimus which is an analogue of rapamycin and 
inhibits mTORC1 activity. However the tumour became insensitive to everolimus 
treatment after 18 month, which was revealed to be due to mutation in MTOR 
(Wagle et al. 2014).  
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1.2.4.3 Parotid tumours 
Different studies have reported nine individual cases of parotid tumours in 
BHD patients to date. First case of parotid oncocytoma in a BHD patient was found 
by Liu et al. Then in 2005 Schmidt et al. found 4 cases of parotid tumours (three of 
which were classified as oncocytomas) in a study of 219 BHD-affected individuals 
(Liu et al. 2000)(Schmidt et al. 2005). Palmirotta et al. also reported a case of BHD 
patient with parotid pleiomorphic adenoma, which was diagnosed before her BHD 
diagnosis (Palmirotta et al. 2008). Maffé et al. has also reported a BHD patient with 
parotid oncocytoma where they also found loss of heterozygosity of FLCN in the 
tumour tissue (Maffé et al. 2011). In a case study of a 45 year old woman with a 
Warthin tumour of the parotid gland, Lindor et al. diagnosed the patient with BHD 
(Lindor et al. 2012). Pradella et al. also reported a BHD patient with parotid 
oncocytoma, however they did not observe any loss of the wild-type FLCN allele in 
the neoplastic tissue (Pradella et al. 2013). Although all these studies provide a link 
between parotid tumour and BHD, there is not enough conclusive statistical evidence 
to consider parotid tumours as clinical manifestation of BHD.  
 
1.3 Folliculin 
The FLCN gene encodes a 579 amino acid protein FLCN that is 64kDa. The 
protein consists of a short hydrophobic N-terminal sequence, one N-glycosylation 
site, three myristoylation sites and a glutamic acid-rich coiled coil domain centrally 
located in the protein (Nickerson et al. 2002). Phosphorylation and ubiquinqtion of 
folliculin has also been observed (Baba et al. 2006)(Dephoure et al. 2008)(Gauci et 
al. 2009)(Piao et al. 2009)(Wang et al. 2010)(Danielsen et al. 2011)(Wagner et al. 
2011). 
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The protein sequence of FLCN is as follows: 
MNAIVALCHFCELHGPRTLFCTEVLHAPLPQGDGNEDSPGQGEQAEEEEGGIQMN
SRMRAHSPAEGASVESSSPGPKKSDMCEGCRSLAAGHPGYISHDKETSIKYVSHQ
HPSHPQLFSIVRQACVRSLSCEVCPGREGPIFFGDEQHGFVFSHTFFIKDSLARGF
QRWYSIITIMMDRIYLINSWPFLLGKVRGIIDELQGKALKVFEAEQFGCPQRAQRMN
TAFTPFLHQRNGNAARSLTSLTSDDNLWACLHTSFAWLLKACGSRLTEKLLEGAPT
EDTLVQMEKLADLEEESESWDNSEAEEEEKAPVLPESTEGRELTQGPAESSSLSG
CGSWQPRKLPVFKSLRHMRQVLGAPSFRMLAWHVLMGNQVIWKSRDVDLVQSAF
EVLRTMLPVGCVRIIPYSSQYEEAYRCNFLGLSPHVQIPPHVLSSEFAVIVEVHAAAR
STLHPVGCEDDQSLSKYEFVVTSGSPVAADRVGPTILNKIEAALTNQNLSVDVVDQ
CLVCLKEEWMNKVKVLFKFTKVDSRPKEDTQKLLSILGASEEDNVKLLKFWMTGLS
KTYKSHLMSTVRSPTASESRN 
The protein sequence of FLCN has proven to be highly conserved in 
vertebrates; however it does not have any significant homology to known proteins. 
The evolutionary analysis performed on the FLCN gene comparing over 5000 mouse 
and human orthologues by Nahorski et al. revealed that at the protein level, FLCN is 
evolving slower than the average gene. It also revealed that FLCN undergoes 
stronger purifying selection than the average gene. This was more noticeable 
between codons 100–230 (Nahorski et al. 2011).  
The FLCN gene, Folliculin (GENBANK accession #BC015687), was mapped 
to the BHD locus 17p12-q11.2 by Khoo et al. 2001 having done a genome wide 
linkage analysis in a large Swedish family with BHD Syndrome (Khoo et al. 2001). 
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BHD is a hereditary syndrome that has an autosomal dominant pattern; 
however the pathogenesis mechanism through mutation of a single FLCN allele 
where a complete loss of the gene does not cause BHD is not fully understood.  
FLCN can be a tumour suppressor gene according to Knudson’s two-hit 
hypothesis. Knudson suggests that predisposition to cancer in some inherited 
diseases is as a result of germline mutation in a tumour suppressor gene together 
with a second somatic mutation in the remaining wild-type copy of the gene. In 2005 
Vocke et al. observed either somatic mutations or loss of heterozygosity in 54 of 77 
(70%) renal tumours in their study (Vocke et al. 2005). Conversely, van Steensel et 
al. studied 5 BHD patients presented with fibrofolliculomas but no kidney tumours 
and did not find any somatic mutation of FLCN or loss of heterozygosity. 
Subsequently they suggested that haploinsufficiency of FLCN is enough to induce 
uncontrolled growth in the skin (van Steensel et al. 2007). Furthermore, in vitro study 
of 10 candidate missense and inframe deletion FLCN mutations by Nahorski et al. 
revealed that the mutant FLCN proteins produced by these mutations are less stable 
and degraded (Nahorski et al. 2011). Although these two studies support the 
haploinsufficiency hypothesis, since deletion of the whole FLCN gene, which is 
observed in Smith-Magenis syndrome (SMS) (OMIM182290) and does not produce 
any of the BHD symptoms (Bi et al. 2002), makes haploinsufficiency hypothesis less 
likely to be the mechanism of pathogenesis in BHD. 
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 Structure and post-translational modifications  1.3.1
 In 2012, Nookala et al. managed to crystallise the C-terminal of FLCN and 
determined its structure by X-ray crystallography (PDB ID: 3V42). The amino acids 
at the C-terminal of FLCN form a core β-sheet with helices on one side, which is also 
followed by an all helical region. This structure is extremely similar to the DENN-
domain proteins (Nookala et al. 2012). Proteins containing DENN-domain are known 
to function as Rab guanine nucleotide exchange factors (GEFs), therefore Nookala 
et al. suggested the Rab GEF role in membrane trafficking for FLCN function 
(Nookala et al. 2012). Using secondary structure prediction computer programmes, 
they also analysed the N-terminal of FLCN; which was predicted to form a longin 
domain. The longin domain is also part of DENN-domain containing proteins that are 
involved in membrane trafficking (Nookala et al. 2012). It is predicted that FLCN 
contains a bipartite tryptophan (WD-WQ) motif within the linker region, which 
consists of 40 amino acids and connects the N-terminal to the C-terminal. The WD-
WQ motif is known to be a binding motif for kinesin light chain 1, which is a cargo 
transporting protein within the cell (Dodding et al. 2011). 
 Baba et al. first identified FLCN phosphorylation which was facilitated by 
FNIP1 and observed by multiple FLCN bands on their Western blots. They 
demonstrate that FLCN phosphorylation is partially reduced upon wortmannin 
treatment (an inhibitor of PI3K), it is drastically reduced upon rapamycin treatment 
(an inhibitor of mTORC1) and that FLCN phosphorylation was completely abolished 
upon treatment of compound C, which is an inhibitor of AMPK. Baba et al. findings 
suggest that FLCN is phosphorylated in the cell by a range of different kinases 
involving in different signalling pathways (Baba et al. 2006). In addition, in a 
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phosphoproteomic study, FLCN was identified as a phosphorylated peptide, further 
confirming that FLCN can exist in a phosphorylated form (Gauci et al. 2009). 
 The first phosphorylation sites identified on FLCN were serine 62 and serine 
302, where serine 302 was suggested to be phosphorylated by an unknown kinase 
downstream of mTORC1 and phosphorylation of serine 62 was shown to be up-
regulated by AMPK indirectly  (Piao et al. 2009)(Wang et al. 2010). Subsequently Yu 
et al. in a global proteomics experiment, identified mTORC1 as the kinase that 
phosphorylates serine 62 and serine 73 of FLCN (Yu et al. 2011). More recently 
Laviolette et al. observed that phosphorylation of serine 62 and serine 73 is at its 
maximum level during the M phase of the cell cycle. Furthermore the FLCN-deficient 
Mouse embryonic fibroblast (MEF) cells were found to develop much quicker through 
the cell cycle process. It was also observed that FLCN in its phosphorylated stated 
(with serine 62 and seine 73 phosphorylated) is a less stable protein suggesting this 
post-translational modification plays an important role in regulation of cell cycle 
(Laviolette et al. 2013).  Another post-translational modification observed in FLCN 
by two independent studies is ubiquitination, where Wagner et al. found lysine 206 
and lysine 559 of FLCN to be ubiquitinated (Danielsen et al. 2011)(Wagner et al. 
2011). However these are both proteomic studies on ubiquitination and a FLCN 
focused study is needed to know more about the relevance of these post-
translational modifications.  
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 Mutations  1.3.2
Using positional cloning Nickerson et al. mapped FLCN to 700 kb on 
chromosome 17p11.2., which was made up of 14 exons. They studied 9 BHD 
families and identified 8 FLCN mutations that were producing a truncated protein; 
five of these mutations were shown to be on exon 11 (Nickerson et al. 2002). 
Additionally they studied 53 probands from BHD families and found 22 further 
mutation in exon 11, indicating exon 11 as a mutation hotspot (Nickerson et al. 
2002). Khoo et al. also identified two mutations in exon 11 in three out of four 
families screened. Furthermore they found mutation in exon 11 in a sporadic case of 
BHD (Khoo et al. 2002). Moreover, Schmidt et al. studied 30 BHD families and their 
combined result with the Nickerson et al. study further established the mutation 
hotspot theory. FLCN germline mutations were identified in 84% of the patients by 
sequence analysis and the majority of these mutations were predicted to produce a 
truncated protein (Schmidt et al. 2005). The first intragenic mutation in BHD patients 
was reported by Benhammou et al. They identified six intragenic deletions and one 
duplication in individuals clinically diagnosed with BHD whom their initial DNA 
sequencing had not revealed any mutations (Benhammou et al. 2011). Figure 1.1 
illustrates FLCN gene with H429X, Y463X and K508R mutatins that were used in 
this study.    
Of all the pathogenic FLCN mutations, approximately 41% are deletion 
mutations, 36% base substitution, 17% duplication and 5% insert/deletion mutation. 
An up-to-date database of all BHD mutations is kept on the Myrovlytis Trust website.   
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Figure 1.1 Schematic illustration of the FLCN gene: the patient mutations used in this study are shown in A, B and C. Three 
patient mutations can result in H429X, the one in red was used in this study. 
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 Interacting partners  1.3.3
1.3.3.1 FLCN interacting protein 1 (FNIP1) 
Baba et al. 2006 first identified FLCN interacting protein 1 (FNIP1). They 
observed that FNIP1 interacts with FLCN and also facilitates phosphorylation of 
FLCN by AMPK. FNIP1 is an evolutionarily conserved protein that also binds AMPK 
and is phosphorylated by AMPK (Baba et al. 2006). FLCN/FNIP1 interaction has 
also been shown to be altered by treatment of AMPK inhibitor (compound C), and 
also with rapamycin and amino acid starvation (Baba et al. 2006). Moreover Yu et al. 
has demonsterated that FNIP1 is phosphorylated by mTORC1,  further placing 
FNIP1/FLCN in energy sensing pathawys (Yu et al. 2011). FNIP1 has also been 
shown to be ubiquitinated at lysine 161 (Wagner et al. 2011). 
FNIP1 as well as FNIP2 is needed for the recruitment of FLCN to the 
lysosomes during amino acid starvation. Furthermore, both FNIP1 and FNIP2 have 
been shown to be essential for interaction between FLCN and the Rag small G 
proteins and that they facilitate the activation of Rags by FLCN (Petit et al. 
2013)(Tsun et al. 2013). 
FNIP1 has also been shown to be involved in B cell development in mice by 
two independent studies published in 2012 (Park et al. 2012)(Baba et al. 2012). 
Behrends et al. found FNIP1 to interact with GABARAP and therefore is likely 
involved in human autophagy (Behrends et al. 2010).  Zhang et al. revealed that 
FNIP1 contains a DENN domain, further implicating FNIP1 in membrane trafficking 
during different steps of autophagy (Zhang et al. 2012). 
 
 20 
 
1.3.3.2 FLCN interacting protein 2 (FNIP2) 
Nagase et al., in a study of human cDNA library found FNIP2 gene, which 
they designated the name KIAA1450 to it then (Nagase et al. 1998). However it was 
not until 2008 that Hasumi et al. identified it as FLCN interacting protein 2 (Hasumi et 
al. 2008). Subsequently Komori et al. found that mouse FNIP2, which they called 
MAPO1, is necessary for apoptosis induced by O6-methylguanine mispairing in DNA 
(Komori et al. 2009). More recently two independent studies also confirmed that 
FNIP2 together with FLCN is required for apoptosis induced by N-Nitroso-N-
methylurea (MNU) (Lim et al. 2012)(Sano et al. 2013).  
FNIP2 is a homologue of FNIP1 with 49% identity, 74% similarity and is highly 
conserved across species. FNIP1 and FNIP2 are able to form homodimers and 
heterodimers. Like FNIP1, it has been shown to bind AMPK and to be 
phosphorylated by AMPK (Hasumi et al. 2008)(Takagi et al. 2008).  
As mentioned before, similar to FNIP1, FNIP2 is required for the recruitment 
of FLCN to the lysosomes (Petit et al. 2013)(Tsun et al. 2013). 
FNIP2 also contains a DENN domain suggesting that it is involved in 
membrane trafficking (Zhang et al. 2012). 
It has been suggested that FNIP2 is required for myelination in the central 
nervous system (Pemberton et al. 2014). In a study by Pemberton et al., a frameshift 
mutation in FNIP2 gene in the Weimaraner dog was found to cause hypomyelination 
of the brain and myelin defect in the spinal cord (Pemberton et al. 2014). 
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1.3.3.3 Plakophilin-4   
Nahorski et al. identified Plakophilin-4 (PKP4) that is also known as p0071, as 
a potential interacting partner for FLCN using yeast-2-hybrid analysis; which was 
then confirmed by co-immunoprecipitation (Nahorski et al. 2012). They also 
observed that FLCN partially co-localises with Plakophilin-4 at cell junctions in the 
interphase; however it is localised at the midbody during cytokinesis (Nahorski et al. 
2012). Using the same approach Medvetz et al. also found that Plakophilin-4 
interacted with FLCN. They demonstrated that cell-cell adhesion and formation of 
desmosomes were negatively regulated by FLCN. Moreover they observed FLCN-
null UOK257 cells had reduced Rho activity and impaired cell migration (Medvetz et 
al. 2012). 
 
1.3.3.4 Rpt4 
Using a Drosophila cDNA library and yeast-2-hybrid, Gaur et al. identified 
Regulatory particle triple-A ATPase 4 (Rpt4) as FLCN interacting partner. This 
interaction was further confirmed in human HEK293 cells where and endogenous 
interaction between FLCN and Rpt4 was detected by co-immunoprecipitation. They 
also suggest a molecular function for FLCN in inhibiting rRNA transcription (Gaur et 
al. 2013).  
 
1.3.3.5 Rag proteins 
 FLCN has reportedly been shown to interact with Rag small G proteins. Petit 
et al. demonstrated that FLCN interacts with RagA via its GTPase domain and this 
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interaction is facilitated by FNIP1. This finding suggests that FLCN could be a 
guanine nucleotide exchange factor (GEF) towards RagA (Petit et al. 2013). 
However, FLCN in complex with FNIP2 was shown to function as a GTPase-
activating protein (GAP) in a study by Tsun et al.. FLCN was found to stimulate GTP 
hydrolysis by RagC and RagD, but not RagA, RagB. It was also found that FLCN 
interaction with Rag proteins is required for activation and recruitment of mTOR to 
the lysosomal membrane during amino acid starvation (Tsun et al. 2013). FLCN was 
demonstrated to interact with inactive Rag heterodimers in Martina et al. study 
whereas TFE3 was shown to interact with active Rags. TFE3 was also shown to be 
phosphorylated at serine 311 upon mTOR activation by FLCN (Martina et al. 2014). 
 
 Signalling pathways 1.3.4
1.3.4.1 Mammalian target of rapamycin (mTOR) signalling 
FLCN was first implicated in mTOR signalling through interaction with AMPK 
which was facilitated by FNIP1 and FNIP2 (Baba et al. 2006)(Hasumi et al. 2008). 
mTOR is a serine/threonine kinase that is highly conserved and has been shown to 
regulate  cell growth, proliferation and metabolism in response to environmental 
changes (Wullschleger et al. 2006). There is compiling evidence suggesting that 
mTOR dysregulation is involved in human disease such as cancer and diabetes 
(Sarbassov et al. 2005)(Landau et al. 2009).  
The exact role of FLCN in mTOR signalling is not quite clear and there are 
contradictory studies regarding FLCN function in this pathway. Three independent 
studies have observed down-regulation of mTOR activity through loss of 
phosphorylation on ribosomal protein S6 (p-rpS6), in FLCN-deficient cells (Takagi et 
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al. 2008)(Hartman et al. 2009)(Bastola et al. 2013). Additionally Hartman et al. 
observed low levels of p-rpS6 (Ser 235/236) in renal oncocytic cysts and tumors 
from the Bhd+/- mice (Hartman et al. 2009).  
Conversely other studies have observed up-regulation of mTORC1 upon loss 
of FLCN expression. When Flcn was knocked out specifically in mouse kidneys by 
Baba et al., although mTOR expression levels were found to be unchanged, 
phosphorylation of rpS6 on Serine 240/244 was shown to be elevated; indicating an 
up-regulation of mTORC1 activity (Baba et al. 2008). Similarly Chen et al. showed 
mTORC1 pathway was activated upon complete loss of Flcn in mouse kidney cysts 
and tumours through phosphorylation of both mTOR and rpS6 (Chen et al. 2008). 
Furthermore, heterozygous loss of Flcn in Flcnd/+ mice, also resulted in higher levels 
of phosphorylated rpS6 protein (Ser240/244) in kidney tumour tissue (Hasumi et al. 
2009). More recently, Hasumi et al. also observed that Flcn knockout mice 
developed cardiac hypertrophy due to increased mTORC1 activity (Hasumi et al. 
2014). Two other clinical studies have also observed increased phospho-mTOR and 
phospho-rpS6 expression in epithelial cells of the pulmonary cysts from BHD 
patients. They postulate that heterozygous loss of Flcn causes dysregulation of 
mTORC1 signalling which leads to formation of the cysts (Furuya et al. 2012)(Nishii 
et al. 2013). 
Remarkably Hudon et al. revealed that depending on the cellular context of 
the Flcn knockout mouse, both elevation and reduction of phosphorylated rpS6 
protein levels could be observed (Hudon et al. 2010). In concordance Khabibullin et 
al. observed a highly cell type dependence modification of mTORC1 signalling upon 
loss of FLCN. Knock down of FLCN in small airway epithelial (SAEC) cells resulted 
in increased mTORC1 activity which was observed by two fold increase in phospho-
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rpS6; whereas FLCN knock down in human bronchial epithelial (HBE) cells did not 
modify mTORC1 signalling (Khabibullin et al. 2014). 
Therefore, this inconsistency observed in mTORC1 signalling in FLCN-
deficient cells and mouse models could be multifactorial. Differences in sample 
preparation, different gene targeting strategies used for making mouse models as 
well as cellular context and cell types, all play a role in different outcome of mTORC1 
signalling upon loss of FLCN. 
 
1.3.4.2 AMP-activated protein kinase (AMPK) signalling 
AMP-activated protein kinase (AMPK) is one of the key regulators of energy in 
eukaryotic cells that restores energy homeostasis through inhibiting anabolic growth 
by repression of the mTORC1 pathway. AMPK also promotes catabolism through 
induction of autophagy and enhances cell survival during periods of starvation when 
energy is in short supply (Alers et al. 2012)(Hardie et al. 2015). FLCN has been 
shown to interact with AMPK and to be phosphorylated by AMPK. Both interaction of 
FLCN with AMPK and its phosphorylation by AMPK is facilitated by FNIP1 and 
FNIP2 (Baba et al. 2006)(Hasumi et al. 2008)(Takagi et al. 2008). Phosphorylation of 
FLCN at serine 62 was shown to increase the affinity of the FLCN/FNIP complex 
towards AMPK, whereas serine 302 phosphorylation decreased the affinity of the 
complex for AMPK (Piao et al. 2009)(Wang et al. 2010). Mouse embryonic 
fibroblasts (MEFs) generated from Flcn–/– (KO) mouse in the Yan et al. study 
displayed increased AMPK activity. Consequently this AMPK activation upon loss of 
Flcn resulted in upregulation of PGC-1α, increased mitochondrial biogenesis, ROS 
production, and HIF activation. When serine 62 within FLCN was mutated to alanine, 
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interaction of the FLCN/FNIP complex with AMPK was reduced and this reduction 
significantly enhanced the phosphorylation of AMPK (Yan et al. 2014). Yan et al. 
data suggests that when the FLCN/FNIP complex is bound to AMPK it can block 
activation of AMPK; since AMPK has been shown to phosphorylate FLCN via FNIPs 
this could indicate a feedback mechanism for the AMPK/FLCN pathway.   
Study on Caenorhabditis elegans (C. elegans) by Possik et al. revealed that 
when flcn-1 was mutated (flcn-1(ok975) mutation), to produce a loss-of-function 
allele, phospho-AAK-2 levels were increased (AAK-2 is an AMPK orthologue). 
Phospho-AMPK levels in MEFs were also observed to be increased upon loss of 
Flcn, which could be rescued back to normal levels when wild type FLCN was re-
expressed in these MEFs (Possik et al. 2014).  
Conversely, isolated primary mouse alveolar epithelial type II cells (AECs) 
from lungs of Flcnf/f:SP-C-Cre mice exhibited significant reduction of  AMPK(Thr172) 
phosphorylation (Goncharova et al. 2014). Subsequently, FLCN-deficient cell 
survival was shown to be increased by 5-aminoimidizole-4-carboxamide riboside 
(AICAR) treatment, and by expressing the constitutively active AMPK (AdAMPK-CA) 
in FLCN-deficient cells (Goncharova et al. 2014). In concordance, Khabibullin et al. 
also showed that FLCN knockdown in HBE cells resulted in reduction of AMPK 
activity; however, AMPK activity was not affected upon loss of FLCN in SAEC cells 
(Khabibullin et al. 2014). Hasumi et al. also observed reduction in phospho-AMPKα 
(Thr172), indicating a decreased AMPK activity in Flcn knockout hearts. Flcn-
deficient hearts had a cardiac hypertrophy phenotype which could be as a result of 
AMPK dysregulation; however, treatment with AICAR or metformin that are both 
AMPK activators did not improve the cardiac phenotype (Hasumi et al. 2014). 
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FLCN together with FNIP2 have been shown to activate AMPK when DNA is 
damaged by alkylating agents, i.e., treatment with N-methyl-N-nitrosourea (MNU), to 
initiate apoptosis (Lim et al. 2012)(Sano et al. 2013).  
Over all, these findings suggest that similar to the effects on the mTORC1 
pathway by FLCN, the effect of FLCN on AMPK signalling pathway is probably highly 
dependent on the cell type. 
 
1.3.4.3 Hypoxia Inducible Factor (HIF) signalling 
In 2011, Preston et al. observed that HIF-induced gene expression during 
hypoxia is negatively regulated by FLCN in hypoxic conditions. In this study, the 
UOK257 cell line was analysed, which is derived from a BHD patients’s renal 
tumour. These UOK257 cells had high levels of HIF activity compared to the cell line 
stably expressing wild type FLCN. Both mRNA and protein levels of HIF-1α and HIF-
2α downstream transcriptional targets, i.e., VEGF-A, BNIP3, CCND1 and GLUT1, 
were shown to be elevated in hypoxia and to a lesser extent under normoxia in 
FLCN deficient cells. However, loss of FLCN did not affect mRNA or protein levels of 
HIF-1α in either hypoxic or normoxic condition; indicating that FLCN regulates the 
transcriptional activity of HIF-1α rather than its expression (Preston et al. 2011). 
Additionally, immunohistochemical staining of HIF-1α, BNIP3, GLUT1 and VEGF-A 
in chromophobe renal carcinoma tumour from a BHD patient, demonstrated nuclear 
localisation of HIF-1α and elevated levels of BNIP3, GLUT1 and VEGF-A compared 
to unaffected tissue to further support this theory (Preston et al. 2011). 
Moreover, histopathological study of the resected lung of a 33 year old 
woman by Nishii et al., revealed that HIF-1α was localised to the nucleus in the cyst-
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lining cells, indicating the activation of HIF-1α transcription target genes. 
Immunohistochemical staining demonstrated elevated levels of VEGF in the cyst-
lining cells and endothelial cells of the wall compared to the normal lung tissue, 
indicative of high HIF-1α activity. In slight contrast to the Preston et al. study, 
western blot analysis revealed HIF-1α protein to be present at higher levels in cystic 
lung tissue compared to the normal lung tissue (Nishii et al. 2013). 
Using a HIF reporter assay, Yan et al. showed that FLCN null MEF cells 
exhibited a two fold increase in HIF activity compared to normal cells in hypoxia. In 
concordance with the Preston et al.’s study they also did not observe any change in 
the expression levels of HIF-1α or HIF-2α protein upon loss of FLCN in MEFs. AMPK 
was observed to be constitutively active in these FLCN null MEFS, which in turn 
resulted in increased PGC1α and mitochondrial biogenesis which led to increased 
production of reactive oxygen species (ROS), which is thought to drive HIF activity in 
this context (Yan et al. 2014). Overall loss of FLCN has been shown to cause an 
elevation in HIF activity; however its mechanism seems to be cell type dependent.  
 
1.3.4.4 The Janus kinase/signal transducers and activators of transcription 
(JAK/STAT) and TGF-β signalling 
The JAK/STAT signalling pathway facilitates cellular responses to the 
chemical signals from outside the cell such as cytokines and growth factors (Mohr et 
al.). Decreased expression of the Drosophila FLCN homologue (dBHD) in the Singh 
et al. study revealed that dBHD was essential for maintenance of male germline 
stem cell (GSC) in the fly testis. Further experiment suggested that dBHD probably 
regulates GSC maintenance downstream of the Decapentaplegic (Dpp) signalling 
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pathway which functions downstream of JAK/STAT signalling pathway. They 
postulated that the dBHD and the Dpp signals synergise on downstream targets 
(Singh et al. 2006). 
Dpp is homologue of the vertebrate bone morphogenetic proteins (BMPs). 
BMPs are members of the TGF-β superfamily, which has been shown to be essential 
for regulation of different cellular functions including stem cell renewal (Ying et al. 
2003)(Tossidou & Schiffer 2012).  
FLCN has been observed to regulate TGF-β signalling by several 
independent studies. Using microarray analysis, Hong et al. observed that TGF-β2 
(TGFB2), Inhibin β A (INHBA, a subunit of activin A), SMAD3 (SMAD3) 
and thrombospondin-1 (THBS1) were down-regulated, and Gremlin (GREM1) was 
upregulated in FLCN-deficient UOK257 cells as well as mutant FLCN-H255R 
UOK257 cells compared to the UOK257 cells expressing wild type FLCN.  
Furthermore, RT-PCR and immunohistochemical staining revealed that genes 
involved in TGF-β signalling (TGFB2, INHBA, SMAD3, THBS1, GREM1) and the 
encoded proteins were dysregulated in renal tumours from BHD patients (Hong et al. 
2010). Cash et al. found that Bhd−/− ES cells display defective TGF-β mediated 
transcriptions such as Bcl-2 Interacting Mediator of Cell Death (BIM). Since 
Trichostatin A (TSA) treatment which is a histone deacetylase (HDAC) inhibitor could 
reverse the biological and molecular defects of Bhd−/− cells; Cash et al. suggest that 
this defect is probably due to HDAC-mediated effects on chromatin at Smad-
dependent promoters (Cash et al. 2011). More recently, using RT PCR, Khabibullin 
et al. found loss of FLCN in in HBE cells resulted in decreased INHBA that is a TGF-
β pathway component. Conversely in FLCN‐deficient SAEC cells increased levels of 
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INHBA was observed while SMAD3 and CDKN2B were decreased (Khabibullin et al. 
2014). 
 
1.3.4.5 Ciliogenesis 
A study carried out by Luijten et al. provided evidence that FLCN has the 
ability to localize in the primary cilia and the motile cilia in HK2 and primary HNE 
cells, respectively. In the same study FLCN was both knocked down and over 
expressed in HK2 cell lines; results demonstrated that after 72 hours fewer cells had 
normal and functional cilia. Of interest after 96 hours the cilia of these cells started to 
function normally similar to the wild type in both experiments. This observation 
suggests that FLCN could be controlling the onset of ciliogenesis. Knowing that the 
existence of cystic lesions are indeed a hallmark of ciliopathies, these cystic lesions 
could be an indication that BHD is also a ciliopathy (Luijten et al. 2013). 
 
1.3.4.6 The Ras-Raf-MAPK signalling 
The Raf-MAPK pathway is one of the most important downstream signalling 
pathways of Ras, a small GTPase protein, known to be frequently mutated and 
dysregulated in various cancers. It has been shown that this pathway is involved in 
cancer progression via cell proliferation, migration, survival, angiogenesis etc. 
(Dhillon et al. 2007). Several studies have indicated that within FLCN-null kidneys 
the Ras-Raf-MAPK pathway seem to be activated due to the loss of FLCN, which 
resulted in abnormal cell growth and proliferation in these cells (Baba et al. 
2008)(Hudon et al. 2010).   
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Of interest, heterozygous loss of Drosophila dBHD in flies with a constitutively 
expressed Ras1 that is involved in MAPK signalling pathway during eye 
development, caused over proliferation and hyperplastic growth of the eye, resulting 
in death (Gaur et al. 2013). Moreover, Gaur et al. also demonstrated that FLCN has 
the ability to interact with Rpt4, causing inhibition of rRNA synthesis within the 
nucleolus in both human and Drosophila cells. Since an increase in rRNA synthesis 
is essential for the activation of the Ras-Raf-MAPK pathway in Drosophila, it could 
be concluded that FLCN acts as an inhibitor towards the Ras pathway (Gaur et al. 
2013). According to the Gaur et al. study the hyperplastic growth seen in BHD 
patients could be partly as a result of increased activation and stimulation of the Ras-
Raf-MAPK pathway and upregulation of rRNA synthesis (Gaur et al. 2013). 
 
1.3.4.7 Wnt/Cadherin signalling pathway 
In order to better understand the targets of FLCN and its role in cell signalling 
pathways, microarray studies were carried out by Reiman et al.. Wnt and cadherin 
signalling genes were shown to be the most differentially expressed genes in FTC-
133 FLCN null cells compared to the wild type (Reiman et al. 2012). The Cadherin 
pathway is known to regulate the formation of cell-cell junctions. Loss of FLCN has 
been shown to cause a reduction in the E-cadherin located at the adherence 
junctions (Nahorski et al. 2012). Additionally, Medvetz et al. demonstrated that FLCN 
null UOK257 cells had increased desmosome formation compared to FLCN 
expressing UOK257 cells and formed both normal and abnormal desmosomes 
(Medvetz et al. 2012). 
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B-catenin is one of the essential components of the Wnt signalling pathway. 
Luijten et al. found that FLCN also played a role in planar cell polarity (PCP) 
regulation via isolating B-catenin in cilia (Luijten et al. 2013). Both pathways have 
been associated with cancer (Jeanes et al. 2008)(Hsu et al. 2012) and could 
possibly contribute to tumourigenesis in BHD patients. 
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1.4 Autophagy 
Autophagy is a biological process that is evolutionarily conserved in 
eukaryotic cells and is vital for cell survival during nutrient starvation where 
intracellular lipid and protein components are broken down to replenish cellular 
energy and amino acid supplies. Basal autophagy also plays an important role in 
maintaining the cellular homeostasis when unwanted or damaged proteins and 
cytoplasmic organelles are degraded (Choi et al. 2013)(Ávalos et al. 2014). Christian 
De Duve first suggested the term autophagy, meaning “self-eating” in Greek, for the 
process in Ciba Foundation Symposium on Lysosomes in 1963 (Klionsky 2008).  
Three different types of autophagy are known; macroautophagy, 
microautophagy, and chaperone-mediated autophagy (CMA). Different types of 
autophagy vary in their function and the manner in which the cargo is delivered to 
the lysosomes. Chaperone-mediated autophagy is the selective type of autophagy. 
In this process cytosolic proteins that contain a pentapeptide motif (which is 
recognised by the chaperone heat shock cognate 70 (Hsc70)), are transferred 
directly to the lysosomes through binding to the receptor lysosome-associated 
membrane protein 2A (LAMP2A). Microautophagy is the process in which 
cytoplasmic materials are engulfed directly by lysosomes that usually involves small 
molecules (Ravikumar et al. 2009) (Ávalos et al. 2014). 
Macroautophagy (referred to as autophagy hereafter) is a cellular process in 
which unwanted cytoplasmic material are sequestered in a double-membrane 
vesicle called the autophagosome. After maturation autophagosomes fuse with 
lysosomes to form autolysosomes, where lysosomal hydrolases digest the 
autophagosome’s material. When degradation is complete, permeases transport 
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amino acids and lipids back into the cytoplasm for recycling (Figure 1.2) (He & 
Klionsky 2009)(Tanida 2011). 
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Figure 1.2 Schematic 
illustration of the 
main autophagic 
events 
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Formation of autophagosomes starts at the phagophore which is the 
assembly sites or precursor for autophagy. Phagophore double membrane assembly 
was postulated to be a de novo process in the cytosol, however quite a few 
laboratories found conflicting data in regard to the presence of ER and golgi markers 
in the phagophore and autophagosome suggesting that the phagophore arises from 
the ER or the golgi complex (Tsukada & Ohsumi 1993)(Strømhaug et al. 1998)(Orsi 
et al. 2010). Activation of the class-III phosphoinositide 3-kinase (PI3K) Vps34, is 
necessary for the formation of phagophores. Vps34 acts in a larger complex with 
Atg14, beclin 1 and AMBRA1. Phosphorylation of Beclin-1 by ULK1 (the mammalian 
orthologue of Atg1) activates the Vps34 complex which in turn initiates autophagy 
(Ravikumar et al. 2009)(Russell et al. 2013). Recruitment of Atg12, Atg5, Atg16 and 
Atg8–PE (phosphatidylethanolamine) are known to be essential for elongation of the 
phagophore membrane (He & Klionsky 2009).  
When the phagophore is sealed, the autophagosome is formed and the cargo 
is delivered to the lysosomes for degradation. Atg8 family of proteins have been 
shown to be vital for the maturation of the autophagosomes. Additionally the 
autophagy initiating complexes such as Atg16 and ULK1 need to dissociate from the 
autophagosome for the lysosomal fusion to occur (Nair et al. 2012)(Ganley 2013). 
In mammalian cells lysosomal membrane protein LAMP-2 and the small 
GTPase Rab7 are known to be required for the fusion of lysosomes and 
autophagosomes (Jäger et al. 2004). Other proteins involved in lysosomal fusion are 
homotypic fusion and protein sorting (HOPs) membrane-tethering complexes and 
soluble N-ethylmaleimide-sensitive factor-attachment protein receptor (SNAREs) 
(Ganley 2013). More recently it was stablished that GABARAP, a sub family of Atg8 
proteins, is needed for the fusion of lysosomes and autophagosomes. It was shown 
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that GABARAP interacts with Phosphatidylinositol 4-kinase IIα (PI4KIIα) and recruits 
it to the lysosomes which facilitates the lysosome/autophagosome fusion (Wang et 
al. 2015). 
The engulfed materials within autolysosome are then degraded by the 
lysosomal acid hydrolases. Vacuolar permeases transport the small molecule 
products of this degradation back to the cytosol to be used in protein synthesis and 
cell maintenance (He & Klionsky 2009). 
 
 Autophagy-related proteins (Atgs) 1.4.1
Studies on Saccharomyces cerevisiae have revealed numerous autophagy-
related (Atg) proteins that are involved in autophagy. Many of these Atg proteins are 
recruited to the phagophore assembly site for the initiation of autophagy (Klionsky et 
al. 2011).  
1.4.1.1 Atg8 family of proteins 
Microtubule-associated protein 1A/1B-light chain 3 (LC3) is encoded by the 
MAP1LC3 gene in humans and is one of the Atg8 family members. LC3 has a 
molecular mass of 17 kDa and is a soluble protein which is spread universally in 
mammalian tissues (Tanida et al. 2008). 
LC3 is present in two forms within the cell the un-conjugated form or LC3I and 
the phosphatidylethanolamine (PE) conjugated or LC3II. LC3I has a cytosolic 
location whereas LC3II is membrane-bound. It has been shown that LC3II localises 
to the autophagosome and is degraded by lysosomal hydrolases after the fusion. 
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Therefore turnover of LC3 can be used as an autophagy marker (Kabeya et al. 
2004)(Klionsky 2005). 
The γ-aminobutyric acid receptor-associated protein (GABARAP) is another 
Atg8 family member that is encoded by the GABARAP gene. It is a 27 kDa protein 
and unlike the first basic alpha-helix amino acid structure of LC3, GABARAP has an 
acidic nature. However GABARAP, similar to LC3 gets conjugated in the cells during 
autophagy and it has been suggested that it functions downstream of LC3 
(Slobodkin & Elazar 2013). GABARAP was first identified as a membrane trafficking 
protein; it has also been linked to SNARE proteins that facilitate intracellular 
trafficking events (Wang et al. 1999)(Elazar et al. 2003). Furthermore, independent 
studies have observed up-regulation of Atg8 family members under different stress 
conditions from yeast to human cell lines (Egami et al. 2005)(van Zutphen et al. 
2010). 
1.4.1.1.1 LIR motif 
Using detailed deletion mapping analyses and X-ray crystallography, LC3-
interacting region (LIR) motifs of p62 and of the Cvt cargo receptor Atg19 were the 
first to be identified. It revealed a short hydrophobic common W-X-X-L motif where X 
can be any amino acid (Pankiv et al. 2007)(Ichimura et al. 2008). Further studies 
have revealed that a LIR motif may also have the sequence of W/F/Y-X-X-L/I/V. It 
has been shown that the F-type LIR motifs evolutionary have a higher affinity for 
GABARAP family of Atg8s (Johansen & Lamark 2011)(Alemu et al. 2012). Serine 
and threonine are used in the X position of the motif dominantly in some LIR 
containing proteins which could be an indication of phosphorylation regulation of the 
region. Additionally the presence of an acidic charge (E, D, S or T) on either N- or C-
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terminal of the motif has been shown to be evolutionary conserved and it has been 
postulated to play a role in the affinity of the interaction (Birgisdottir et al. 2013). 
 
 p62 (Sequestosome 1, SQSTM1) 1.4.2
p62 is a protein encoded by the SQSTM1 gene in humans. It was the first 
autophagy protein to be implicated in selective autophagy (Pankiv et al. 2007). It is 
also known that p62 functions as a scaffold protein in the NF-kB pathway (Moscat et 
al. 2007). Mice knockout studies of p62 by Komatsu et al. has shown that p62 can 
bind to LC3 and ubiquitin to regulate the formation of protein aggregates (Komatsu et 
al. 2007). Furthermore p62 is known to regulate apoptosis through activation of 
polyubiquitinated caspase-8 by promoting aggregation of CUL3-modified caspase-8 
which leads to the full activation of apoptotic process (Jin et al. 2009). 
p62 contains few well known domains, such as a zinc ﬁnger(ZZ), a tumour 
necrosis factor receptor associated factor 6 (TRAF6) and a LIR; the presence of 
these multiple domains indicates multifunctional activity of the protein. P62 is 
dominantly a cytoplasmic protein however, its presence in the nucleus has been 
observed as well ((Kabeya et al. 2004).   
The removal of p62 from the cytoplasm is predominantly done via autophagy 
therefore the amount of p62 is generally used as readout of autophagic activity. p62 
accumulation in immunocytochemistry or increased levels of p62 via western blots 
are usually an indication of autophagy impairment (Pircs et al. 2012)(Lippai & Lőw 
2014). 
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 unc-51 like autophagy activating kinase 1 (ULK1) 1.4.3
ULK1 is the mammalian orthologue of Atg1 which is a serine/threonine 
kinase. It functions at the initiating step of autophagy and its kinase activity is 
necessary for assembly and formation of autophagosomes (Itakura & Mizushima 
2010). Yeast studies have revealed that upon starvation Atg1 in a complex with four 
other Atg proteins Atg13, Atg17, Atg29, and Atg31 recruits Atg9 and the autophagy-
specific PI3K complex to the phagophore which results in recruitment of the Atg2-
Atg18 complex and the Atg conjugation systems (Suzuki et al. 2007). When Atg1 
complex is formed the kinase activity of Atg1 becomes elevated which is required for 
cycling of the Atg protein within the phagophore and autophagy progression 
(Reggiori et al. 2004)(Noda & Inagaki 2015). 
There are two orthologues of the yeast Atg1 in mammals ULK1 and ULK2. 
ULK1 in a complex with ATG13, FIP200 and ATG101 drives autophagosome 
formation and the complex is positively regulated by many internal ULK1-mediated 
phosphorylation events, including ULK1 autophosphorylation (Jung et al. 
2009)(Ganley et al. 2009). It has been shown that ULK1 can be phosphorylated at 
multiple sites however not all the kinases responsible for ULK1 phosphorylation have 
been identified. Similar to yeast Atg1, ULK1 autophosphorylation is demonstrated to 
be crucial for elevated activity and stability of the complex (Dorsey et al. 2009). 
Downstream ULK1 substrates are gradually being identified. AMBRA1 was 
the first ULK1 substrate identified that is integral to the autophagy machinery but is 
not a component of the ULK1-ATG13-FIP200 complex (Löffler et al. 2011). More 
recently, ULK1 phosphorylation of ATG9 was identified as an important step during 
expansion of the isolation membrane (Papinski et al. 2014). Additionally, a further 
molecular link has been identified, whereby active ULK1 can directly phosphorylate 
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Beclin1, allowing pro-autophagy Vps34 complexes to promote autophagy induction 
and autophagosome maturation (Jung et al. 2011). ULK1 is known to indirectly 
impact autophagy via phosphorylation of both AMPK and Raptor within mTORC1 
(Löffler et al. 2011)(Jung et al. 2011). It was revealed that ULK1 phosphorylates 
Raptor at multiple serine and a threonine sites (Ser696, Ser792, Ser855, Ser859, 
Ser863, Ser877 and Thr706). Raptor phosphorylation by ULK1 and also their direct 
interaction was shown to impair the interaction between mTORC1 and Raptor 
(Dunlop et al. 2011). 
It has been established that the phosphorylation status of the ULK1 complex 
drastically changes with the nutrient status of the cell and the complex is regulated 
by both mTORC1 and AMPK (Alers et al. 2012).  
When growth conditions are optimal, mTORC1 phosphorylates Atg13 and 
Ulk1/2 via their interaction with raptor which in turn disables the kinase activity of 
ULK1/2 (Ganley et al. 2009). Upon starvation, the inhibitory mTORC1 
phosphorylation sites become dephosphorylated and the pre-activated ULK1 
becomes autophosphorylated to further enhance ULK1. ULK1 also phosphorylates 
FIP200 and Atg13 within the complex which causes the complex to translocate to the 
phagophore (Hosokawa et al. 2009).  
ULK1 has been shown to directly interact with AMPK and to be 
phosphorylated by AMPK. AMPK positively regulates ULK1 activity via 
phosphorylation (Kim et al. 2011)(Bach et al. 2011). 
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 AMP-activated protein kinase (AMPK) 1.4.4
AMPK is a serine/threonine kinase that was originally found to phosphorylate 
and inactivate several lipogenesis enzymes. AMPK is known as an evolutionarily 
conserved protein that plays an important role in energy-sensing in the cell which is 
activated by metabolic stress (Hardie 2007). Studies on Saccharomyces cerevisiae 
revealed that SNF1, the yeast orthologue of AMPK, positively regulates autophagy 
(Wang et al. 2001). Using HT-29 cells and HeLa cells it was demonstrated that 
autophagy was inhibited when the cells were treated with compound C which is an 
inhibitor of AMPK. This evidence suggests an essential role for AMPK in the 
regulation of autophagy in mammals (Meley et al. 2006). Under starvation, AMPK is 
activated via LKB1 and increased AMP concentration in the cell which leads to 
activation of Tuberous Sclerosis Complex 1 and 2 (TSC1/2), which inhibits signal 
transduction through Rheb/mTORC1. However, it has been suggested that other 
conditions apart from starvation also regulate autophagy through activation of AMPK. 
Activation of Ca2+/calmodulin-dependent kinase kinase-β (CaMKK-β) by Ca2+ 
mobilizing agents such as vitamin D compounds, thapsigargin, ATP and ionomycin,  
activate AMPK when free cytosolic Ca2+ is increased; which has been shown to drive 
autophagy in human breast cancer and cervix carcinoma cells (Høyer-Hansen et al. 
2007). Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has 
also been shown to induce autophagy through transforming growth factor-β-
activating kinase 1 (TAK1)-mediated activation of AMPK in MCF10A cells (Herrero-
Martín et al. 2009). 
When cells are deprived of energy, AMPK directly binds to and 
phosphorylates ULK1, inducing autophagy. Multiple ULK1 residues have so far been 
identified to be phosphorylated by AMPK. Egan et al. found Ser467, Ser555, Thr574 
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and Ser637 on ULK1 as potential AMPK phosphorylation sites of which three sites 
(Ser555, Thr574 and Ser637) were confirmed as direct AMPK phosphorylation sites 
by tandem mass spectrometry and in vitro kinase assays (Egan et al. 2011). Two 
further AMPK phosphorylation sites were uncovered subsequently on ULK1 as 
Ser317 and Ser777. It was demonstrated that phosphorylation of Ser317 and Ser777 
by AMPK is required for efficient autophagy induction (Kim et al. 2011). Bach et al. 
also identified Ser555 as the AMPK phosphorylation site on ULK1. It was shown that 
ULK1/14-3-3 binding is mediated through AMPK phosphorylation of Ser555 (Bach et 
al. 2011).  
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 Mammalian/mechanistic target of rapamycin (mTOR) 1.4.5
TOR1 and TOR2 genes were first identified in Saccharomyces cerevisiae 
when the yeast was being screened for resistance to the drug rapamycin (Heitman et 
al. 1991). mTOR is a serine/threonine protein kinase that has been shown to be 
involved in cellular process including cell growth, cell proliferation, cell motility, cell 
survival, protein synthesis, transcription and autophagy (Huang & Fingar 2014). 
mTOR interacts with other proteins and forms two different kinase complexes in the 
cell called mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) that have 
distinct functions. However, it’s only mTORC1 that is affected by rapamycin 
treatment; at least with short term, treatment (Wullschleger et al. 2006). mTORC1 
consists of mTOR, mLST8 (or GβL), and the regulatory-associated protein of TOR 
(raptor); and mTORC2 consists of mTOR, mLST8, Rictor, Sin-1 and Protor-1/2 (Kim 
et al. 2002). Although rapamycin has been shown to strongly induce autophagy in 
yeast, in mammalian cells rapamycin has proven to be less effective at autophagy 
induction and appears to be cell line dependent. It has been suggested that this 
partial induction of autophagy is as a result of rapamycin only inhibiting 
phosphorylation of S6K1 and not other mTORC1 substrates. Moreover, treatment 
with Torin1 (a member of the pyridinonequinoline class of kinase inhibitors) as an 
ATP-competitive mTOR inhibitor potently induced autophagy in in both MEFs and 
HeLa cells (Thoreen & Sabatini 2009)(Thoreen et al. 2009).  
When Akt is activated by growth factors, it is relocated to the plasma 
membrane and is phosphorylated by PDK1. Subsequently Akt phosphorylates 
tuberous sclerosis complex 2 (TSC2), which inactivates the TSC1/TSC2 complex. As 
TSC1/2 acts as a GAP towards Rheb, this in turn promotes formation of GTP-Rheb 
which results in direct activation of mTORC1 (Long et al. 2005)(Huang & Manning 
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2009). Additionally, one of mTORC1 components PRAS40, was shown to be a direct 
substrate to Akt and its phosphorylation upon insulin induction was observed to 
activate mTORC1(Vander Haar et al. 2007). It can be concluded that removal of 
growth factors and amino acid starvation can result in mTORC1 inactivation which 
leads to autophagy induction.   
The presence of amino acids and nutrient availability has also been shown to 
be a positive regulator of the mTORC1 activity through the Rag small G proteins.  
Rags are a group of small G proteins that can form heterodimers and bind directly to 
mTORC1 to localise it to the lysosomes where GTP-Rheb is located. Expression of 
an active Rag mutant (RagBGTP-DGDP) in human embryonic kidney (HEK)-293T cells 
increased the binding of mTORC1 to these Rags and made the mTORC1 pathway 
insensitive to amino acid starvation. In the presence of amino acids, RagA and RagB 
are GTP-bound and recruit mTORC1 to lysosomal membranes (Sancak et al. 
2008)(Sancak et al. 2010). More recently, Demetriades et al. demonstrated that Rag 
GTPases also bind TSC2 which is dependent on the amino acid levels of the cells. It 
was also shown that TSC2 is recruited to the lysosomes upon amino acid starvation 
which was observed to be necessary for inactivation of mTORC1 (Demetriades et al. 
2014).  
As mentioned before, mTORC1 interacts with ULK1 and can directly 
phosphorylate ATG13 and ULK1. Phosphorylation of ULK1 Ser757 by mTORC1 has 
been demonstrated to be of importance for ULK1 inhibition. By repressing the kinase 
activity of the ULK1 complex, mTORC1 acts as one of the fundamental inhibitors of 
the autophagy (Dorsey et al. 2009)(Kim et al. 2011)(Kang et al. 2013).  
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 Rabs 1.4.6
Other than the main autophagy proteins, additional regulators such as the 
Rab small G proteins are also involved in autophagy. Rab GTPase proteins are part 
of the Ras-like GTPase superfamily which regulate vesicular trafficking (Chua et al. 
2011). All Rab small G proteins (like other GTPases) are either GDP-bound, which is 
the inactive form, or GTP-bound which is the active form. It has been shown that 
Rab-GDP has a cytoplasmic location while Rab-GTP has a membrane location 
(Bento et al. 2013). Rabs switch between active GTP-bound and inactive GDP-
bound states, and are regulated by guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs) (Barr & Lambright 2010). 
A number of Rab small G proteins have been found to be involved in the 
different stages of autophagy including Rab1, Rab5, Rab7, Rab8A and B, Rab9A, 
Rab11, Rab23, Rab24, Rab25, Rab32, and Rab33; however the exact function of 
these Rabs has not been fully characterised (Ao et al. 2014). Rab7 has been shown 
to be involved in autophagosome maturation and lysosomal fusion during autophagy 
(Gutierrez et al. 2004)(Mizushima & Komatsu 2011). Ypt7 (the yeast orthologue of 
Rab7) was first implicated in the fusion of autophagosomes with the vacuole in 
Saccharomyces cerevisiae, where yeasts lacking the Ypt7 displayed accumulation of 
autophagosomes (Kirisako et al. 1999). Rab24 has also been shown to localise to 
endoplasmic reticulum (ER) and was found to be involved in autophagosome 
maturation (Ao et al. 2014). The involvement of Rab24 in autophagy was confirmed 
when immunohistochemistry studies in neuronal PC12 cells revealed co-localisation 
of Rab24 with LC3 (Egami et al. 2005). Hirota & Tanaka have demonstrated that 
Rab32 localises to the ER in HeLa cells and COS cells and is necessary for 
autophagic vacuole formation. Furthermore, knockdown of Rab32 was shown to 
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impair basal autophagy which was demonstrated by accumulation of p62 and LC3II 
(Hirota & Tanaka 2009).  
 
1.5 Aims and objective of this project 
Although advances have been made recently in regards to BHD, it still 
remains a poorly understood disease. To better understand BHD, the main aims of 
this study were: 
I) To examine the role of FLCN in the context of autophagy. 
II) To characterise and better understand the role of FLCN interacting 
partners FNIP1 and FNIP2 and to further investigate FLCN’s  cellular 
function. 
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2 Chapter 2: Materials and methods 
2.1 Reagents and chemicals 
3-[(3-Cholamidopropyl)dimethylammonio]-1-Propanesulfonate (CHAPS), Thermo 
scientific, cat no: 28300 
Agar, Sigma, cat no: A1296 
Ampicilin sodium salt, Sigma, cat no: A0166-5G 
Calcium chloride, 1mol/l, BDH/VWR, cat no: 190464K 
Calcium chloride, dihydrate, Sigma, cat no: C3306 
Chloroquine diphosphate, Sigma, cat no: C6628 
Dimethyl Sulphoxide (DMSO), Sigma, cat no: D8418 
Dithiothreitol (DTT), Sigma, cat no: 43816/646563 
Dulbecco’s Modified Eagle Medium (DMEM), Gibco, Invitrogen, cat no: 41966-029  
Ethanol, Fisher Scientific, cat no: E/06500F/17 
Foetal Bovine Serum (FBS), Gibco, Life Technologies, cat no: 10270-106  
Glucose, Sigma, cat no: G7528 
Glycerol, Sigma, cat no: G6279 
Glycine, Sigma, cat no: G8898, G8790 
HEPES, Sigma, cat no: H3375 
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Hydrochloric acid, Sigma, cat no: 320331 
Kanamycin Sulfate, Roche, cat no: 90522923  
Magnesium chloride, anhydrate, Sigma, cat no: M8266 
Magnesium chloride, hexahydrate, Sigma, cat no: M2670 
Mercaptoethanol, Sigma, cat no: M3148 
Methanol, Fisher Scientific, cat no: M/3900/17 
N,N,N,N-tetramethylethylene diamine (TEMED), Sigma, cat no: T9281 
Penicillin-Streptomycin (5,000 U/mL), Gibco, Life Technologies, cat no: 15070-063 
Penicillin G sodium salt, Sigma, cat no: P3032 
Potassium chloride, Sigma, cat no: P9333 
Powdered Milk, Marvel, cat no: 92964 
Protogel 30%-acrylamide, National diagnostics, cat no: EC-890 
Protogel-resolving buffer, National diagnostics, cat no: EC-892 
Protogel-stacking buffer, National diagnostics, cat no: EC-893 
Puromycin, Invitrogen, cat no: A11138-03 
Recovery cell culture freezing medium, Gibco, Invitrogen, cat no: 12648-010 
Sodium bicarbonate, Sigma, cat no: S5761 
Sodium chloride, Sigma, cat no: S7653 
Sodium Dodecyl Sulfate (SDS), Sigma, cat no: L6026 + L4390 
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Sodium fluoride, Sigma, cat no: S7920 
Sodium hydroxide, Sigma, cat no: S8045 
Sodium orthovanadate, Sigma, cat no: 450243 
Streptomycin sulphate, Invitrogen, cat no: 15140-122 
Tris, Sigma, cat no: 15,456,3 
Triton X-100, Sigma, cat no: T8787 
Trypsin-EDTA solution, Invitrogen, cat no: R-001-100 
Tryptone, Bacto, Becton Dickinson, cat no: 211705 
Tween 20, Sigma, cat no: P1379 
Yeast extract, Bacto, Becton Dickinson, cat no: 212750 
 
2.2 Buffers and solutions 
BHD lysis buffer  
20 mM Tris, 135 mM NaCl, 5 % (v/v) glycerol, 50 mM NaF and 0.1 % (v/v) Triton X-
100, pH 7.5  
Buffer B 
40 mM HEPES, 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM β-
glycerophosphate, 50 mM NaF, 1.5 mM Na3VO4, 0.3% (w/v) CHAPS, pH 7.5 
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Krebs Ringer buffer (KRB) 
20 mM HEPES, 115 mM NaCl, 5 mM KCl, 10 mM NaHCO3, 2.5 mM MgCl2, 2.5 mM 
CaCl2, pH 7.4 
Luria Broth (LB) 
15g Tryptone, 7.5g Yeast Extract, 15g NaCl, 1.5g Glucose, 1.5g Anhydrous MgCl 
Combine with 1.5l of dH20 and adjust to pH 7.0 before autoclaving. 
Luria Agar 
10g Tryptone, 5g Yeast Extract, 10g NaCl, 1g Glucose, 1g Anhydrous MgCl 
Add 1l of dH20 and adjust pH to 7.0 before adding 15 g Agar, 2ml of 1M NaOH 
Autoclave for 12 min before pouring. 
Phosphate-Buffered Saline (PBS) (1X) 
One tablet dissolved in 200 mL of deionized water (Sigma, cat no: P4417) 
TBS  
Add 2.42g Tris-base and 8g NaCl to 1l of dH20. Adjust pH to 7.6 
TBS-T 
Add 2.42g Tris-base and 8g NaCl to 1l of dH20. Adjust pH to 7.6 and add 1ml 
Tween-20 to give 0.1% (w/v)  
Low Salt Wash Buffer 
40mM HEPES, 2mM EDTA, 10mM β-Glycerophosphate, 150mM NaCl, 0.3% (w/v)  
CHAPs, pH 7.4 
 51 
 
High Salt Wash Buffer 
40mM HEPES, 2mM EDTA, 10mM β-Glycerophosphate, 400nM NaCl, pH7.4 
Western Transfer Buffer x 10 
144.07g Glycine, 30.285g Tris-Base, 2g SDS 
Make up to 1l with dH20 
Running Buffer x 10 
144.07g Glycine, 30.285g Tris-Base, 10g SDS 
Make up to 1l with dH20 
Running buffer  
3-8% gels: NuPAGE® Tris-Acetate SDS Running Buffer (Life technologies, cat no: 
LA0041)  
4-12% gels: NuPAGE® MES SDS Running Buffer (Life technologies, cat no: 
NP0002)  
 
 
 
 
 
 52 
 
2.3 Antibodies  
β-actin, Polyclonal, Rabbit, Cell Signalling, cat no: 4967 
Flag, Monoclonal, Mouse, Sigma, cat no: A8592 
FLCN, Polyclonal, Rabbit, A kind gift from Prof. Arnim Pause (McGill University, 
Canada) 
FNIP1, Monoclonal, Rabbit, abcam, cat no: ab134969 
GABARAP, Polyclonal, Rabbit, ABGENT, cat no: AP1821a 
Goat HRP conjugated, Sigma, cat no: A9452 
GST, Monoclonal, mouse, Merck Millipore, cat no: 05-782 
Guinea pig HRP conjugated, Sigma, cat no: A5545 
HA, Monoclonal, Rat, Roche, cat no: 11 867 431 001 
HIF1α, Monoclonal, Mouse, BD Biosciences, cat no: 610959 
LC3, Polyclonal, Rabbit, NovusBiologicals, cat no: NB100-2220 
Mouse HRP conjugated, Sigma, cat no: RABHRP1 
Myc, 9E10, Monoclonal, Mouse, Sigma, cat no: M5546 
NUP155, Polyclonal, Rabbit, abcam, cat no: ab157104 
p62, Polyclonal, Guinea pig, Progen Biotechnik, cat no: GP62-C 
Rab35, Polyclonal, Rabbit, Proteintech, cat no: 11329-2-AP 
Rabbit HRP conjugated, Sigma, cat no: RABHRP2 
 53 
 
Rat HRP conjugated, Sigma, cat no: A5795 
SUZ12, Monoclonal, Rabbit, Cell Signalling, cat no: 3737 
ULK1, Polyclonal, Rabbit, Cell Signalling, cat no: 4773 
V5, Monoclonal, Mouse, Invitrogen, cat no: R960-25, R961-25 
 
2.4 Plasmids 
Flag-NUP155, was a kind gift from Dr Qing Kenneth Wang, Ph.D., M.B.A. Director of 
Centre for Cardiovascular Genetics Cleveland Clinic Professor of Molecular 
Medicine Professor of Genetics, Case Western Reserve University.  
GST-FLCN, was generated in pDEST27, using the Gateway system (Life 
Technologies). 
HA-FLCN, was generated in the pN3HA backbone (a kind gift from Dr. Sylvia 
Neumann, The Scripps Research Institute, San Diego, USA). This plasmid was used 
to generate all the mutant constructs of FLCN in this study, using site-directed 
mutagenesis (Agilent technologies). 
HA-FNIP1, was a kind gift from Dr. Laura Schmidt (National Institutes of Health, 
Bethesda, USA). 
HA-GABARAP, from pDONR35 was cloned into pcDNA-HA, using the Gateway 
system (Life Technologies). 
HA-LC3B, was cloned into pDEST15, using the Gateway system (Life Technologies) 
HA-p62,   from Addgene, Plasmid #28027.  
Myc-FNIP2, was a kind gift from Dr. O. Hino (Juntendo University School of 
Medicine, Tokyo, Japan). 
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ptfLC3, from Addgene Plasmid #21074.  
Untagged-FLCN, was generated in the pcDNA3.1 vector, using the Gateway system 
(Life Technologies). 
V5-FNIP1, was generated in pcDNA3.1/nV5-DEST, using the Gateway system (Life 
Technologies). 
V5-ULK1, wild type was subcloned from IMAGE clone 3526749 (Source Bioscience 
LifeSciences), into pcDNA3.1 using the Gateway system (Life Technologies). The 
kinase dead ULK1 mutant, K46I, was made using site-directed mutagenesis (Agilent 
Technologies, 200521). 
 
2.5 Methodology  
 Cell culture  2.5.1
All cell lines were cultured in DMEM supplemented with 10 % (v/v) foetal calf 
serum, 100 U/ml penicillin and 100 μg/ml streptomycin, unless otherwise stated. 
Once confluent, cells were passaged as follows, cell lines were washed twice in 
trypsin, this was removed via aspiration before a 5 min incubation at 37 ºC. Cells 
were then resuspended in DMEM and transferred to a new flask.  
For long term storage, cells were frozen down in recovery cell culture freezing 
medium (Gibco, Invitrogen) using cryogenic freezing container and stored in 
cryogenic vials in liquid nitrogen. 
For complete starvation, cells were washed twice in phosphate buffered saline 
(PBS) and incubated in Krebs Ringer buffer (KRB) for 4 h. 
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To harvest the cells, plates were washed once in PBS before being resuspended in 
lysis buffer supplemented with protease inhibitors (1mM Na3VO4, 2µM antipain, 
10µM leupeptin, 1µg/ml pepstatin, 0.1mM PMSF, 1mM DTT and 1mM benzamidine) 
Cells were incubated on ice for 20 min to aid lysis then centrifuged for 8 min at 4 ºC, 
13.000rpm. 
 Transfection 2.5.2
Cells were transfected using Lipofectamine® 2000 Reagent (Life 
Technologies) according to the manufacturer’s protocol. Cells were 70-90 % 
confluent at the time of transfection. Cells were harvested 24–36 h post-transfection 
in BHD lysis buffer (unless otherwise stated) and cell lysate was centrifuged and 
protein quantified using Bradford reagent (Sigma-Aldrich). The experiments were 
either performed immediately or cell lysates were stored at –80 ºC for further 
analysis. 
For large scale transfections, CaCl2 transfection was used. DNA complexes 
were prepared by combining the DNA with ddH2O, CaCl2 was then added and the 
solution was vortexed. BES solution was then slowly added dropwise whilst aerating 
the sample with a drawn glass pasteur pipette. Mixtures were left to stand at room 
temperature for 15-20 min (until precipitate becomes visible) then added dropwise to 
the cells.  Media was changed on day two and cells were harvested on day three. 
 Bradford protein assay 2.5.3
A standard curve was set using BSA dissolved in dH20. To analyse total 
protein, 12.5µl of sample was diluted into 750µl of Bradford reagent and absorbance 
measured at 595nm using the Jenway Genova Spectrophotometer. 
 
 56 
 
 In vivo radiolabelling  2.5.4
Transfected HEK293 cells were incubated in phosphate-free medium 
containing 0.2 mCi [32P]-orthophosphate (PerkinElmer) for 4 h. These cells were 
harvested using BHD lysis buffer. HA-FLCN was immunoprecipitated with anti-HA 
antibody bound to protein G-Dynabeads (Life Technologies) and washed in lysis 
buffer. 
 Immunoprecipitation (IP) 2.5.5
Cell lysates were diluted in 500 µL BHD lysis buffer (plus protease inhibitors) 
and rotated with 1 µL of the appropriate antibody at 4 °C for 2h. 20 μL of a 50:50 
slurry of protein-G Sepharose beads(GE Healthcare Life Sciences) were then added 
and samples were rotated for another hour at 4 °C. Beads were then washed three 
times in BHD lysis buffer (plus protease inhibitors) before elution in 40 μL of 1x 
sample buffer (from 4xNuPAGE LDS sample buffer, Life Technologies). 
 GST purification  2.5.6
Samples for GST-pulldown were lysed in Buffer B plus protease inhibitors 
(without the addition of DTT) and incubated with glutathione-Sepharose beads (GE 
Healthcare Life Sciences). Beads were washed three times in lysis buffer, and GST-
tagged proteins were eluted using 10 mM glutathione. 
 Western blot analysis  2.5.7
The Invitrogen NuPage Novex gel system was used for electrophoresis. 3-8 
% Tris-acetate gels or 4-12 % Bis-Tris gels were used depending on the molecular 
size of the protein of interest. Samples were prepared in 4x sample buffer and 
incubated at 70 ºC for 10 min prior to loading. Gels were run at 150 V for 1 h and 
proteins were transferred to a polyvinylidene fluoride membrane (PVDF) at 25 V for 2 
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h in transfer buffer using the wet transfer system. After transfer, the membrane was 
blocked in 5% (w/v) dry milk powder in TBS-T for a minimum of 2 h. The membrane 
was then incubated overnight in primary antibody in 2% BSA/TBS-T. The following 
day membranes were washed three times in TBS-T and then incubated in 1:10000 
dilution of the appropriate HRP-conjugated secondary antibody for a minimum of 30 
min. Following three further TBS-T washes, membranes were incubated in 
Enhanced Chemiluminesence (ECL) solution (Amersham) for 1 min. 
Autoradiography films were then used to visualise the signal.   
 Site-Directed Mutagenesis 2.5.8
The QuikChange II XL Site-Directed Mutagenesis Kit, 10 Rxn (Agilent 
Technologies) was used to make the mutation constructs. PCR reactions were 
performed according to the manufacturer’s protocol and cycling conditions. 
Following PCR, 1 μL of the Dpn I restriction enzyme (10 U/μL) was added directly to 
each PCR reaction. Reactions were incubated at 37 °C for 1 h to digest the parental 
DNA. 
XL1-Blue supercompetent cells were thawed on ice. For each reaction to be 
transformed, 50 μL of the supercompetent cells was added to a prechilled 14-ml BD 
Falcon polypropylene round-bottom tube. 1 μL of the Dpn I-treated DNA from each 
reaction was transferred to separate aliquots of the supercompetent cells. The 
transformation reactions were incubated on ice for 30 min, heat shocked for 45 s at 
42 °C and then placed on ice for a further 2 min.  0.5 mL of NZY broth or SOC 
medium, preheated to 42 °C, was added per tube and the transformation reactions 
were incubated at 37 °C for 1 h with shaking at 225–250 rpm. The appropriate 
volume of each transformation reaction was spread on agar plates containing the 
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appropriate antibiotic for the plasmid vector. The transformation plates were 
incubated at 37 °C for >16 h. Resulting colonies were purified and sequenced to 
check for the presence of desired mutation. 
 Plasmid purification (Miniprep/ Maxiprep) 2.5.9
Three colonies from each plate of site-directed mutagenesis was picked and 
grown over night in 5 mL LB broth containing the appropriate antibiotic (in order to 
have at least one correct and in frame desired mutated sequence). Bacterial cells 
were pelleted and the plasmid DNA was extracted using QIAprep® Miniprep kit 
(QIAGEN) according to the manufacturer’s protocol. 
Once the sequence was verified, for large scale plasmid purification, each 
colony was grown in a starter culture of 5 mL LB medium containing the appropriate 
selective antibiotic. It was incubated for 4-5 h at 37°C with vigorous shaking (250 
rpm). The starter culture was then diluted in 500mL of LB medium containing the 
appropriate selective antibiotic and incubated overnight (12-16h) at 37°C with 
vigorous shaking (250 rpm). The bacterial cells were harvested by centrifugation at 
6000 x g for 15 min at 4°C. The plasmid DNA was extracted using QIAprep® 
Maxiprep kit (QIAGEN) according to the manufacturer’s protocol. 
 Sequencing 2.5.10
The purified plasmids were sent to Eurofins MWG Operon for sequencing. 
 Cyquant cell proliferation assay 2.5.11
Cells were seeded at 4000 per well of a 96 well plate. Cells were treated with 
appropriate drug for 24 h or 48 h, the media was then removed and the plate was 
frozen at –80 ºC.  Cell proliferation rate was determined using the CyQuant® Cell 
Proliferation Assay Kit (Life Technologies) following the manufacturer’s protocol. 
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Essentially, lysis buffer containing CyQUANT GR dye was added to each well and 
gently pipette to allow lysis of the cells and incorporation of the dye to the DNA. 
Fluorescence was detected by excitation at ~485 nm and emission detection at ~530 
nm using a plate reader. Cell number was calculated using a standard curve 
generated from 250 to 50000 cells. 
 RNA extraction 2.5.12
For the extraction of mRNA, cells were harvested in RNA protect Cell 
Reagent and centrifuged at 5,000 rpm for 5 min to produce a pellet, the supernatant 
was discarded and the pellet was saved for mRNA extraction. mRNA was extracted 
using the Qiagen mRNA extraction kit in accordance with manufacturer’s protocol, 
QIA shredders (QIAGEN) were utilised to homogenise the pellet. Resulting mRNA 
concentration was determined using the nanodrop spectrophotometer.   
 Reverse transcription 2.5.13
To prepare the complementary DNA (cDNA), first the genomic DNA (gDNA) is 
eliminated using gDNA Wipeout Buffer, 7x (QIAGEN) and total RNA from each 
sample (up to 1 μg) in a 14 µl volume reaction which is incubated at 42°C for 2min. 
The reverse transcription reaction is prepared as follows: 
Quantiscript Reverse Transcriptase  1 µl 
Quantiscript RT Buffer, 5x                 4 µl 
RT Primer Mix                                    1 µl 
gDNA eliminated reaction                  14 µl 
This reaction was incubated in a thermal cycler (Applied Biosystems) with the 
following cycle: 
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42 °C for 30min 
95 °C for 3min 
The product was stored on ice for real-time PCR. 
 Quantitative-PCR 2.5.14
Quantitative real-time PCR reactions were conducted in 96-well plates using 
appropriate primer assays and Sybr Green PCR Master mix (QIAGEN). Amplification 
was performed as follows: 
1. Initial denaturation step (95 °C, 15 min) 
2. 40 cycles of denaturation (94 °C, 15 s) 
3. Annealing step (55 °C, 30 s) 
4. Extension step (72 °C, 40 s).    
The amplification products were quantified during the extension step in the 
fortieth cycle. The results were then determined using the ddCT (delta-delta-Ct) 
method, and standardised to β-actin. A dissociation step was performed, which 
verified that only one PCR product was produced with each primer set to show the 
specificity of each primer. 
 Modelling of FLCN structure  2.5.15
Crystal structure coordinates used in this study are as deposited in the protein 
data bank (PDB Id: 3V42). The model was generated using PyMOL v.1.3. 
 Densitometry 2.5.16
The density of the visualised bands in western blotting was measured and 
analysed using the Image J. program version 1.46.  
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 Statistical analysis   2.5.17
One way ANOVA followed by LSD post-hoc testing (as appropriate) was used 
for statistical analysis, with p < 0.05 taken to be significant. 
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3 Chapter 3: Involvement of FLCN in autophagy 
3.1 Introduction 
Autophagy is an evolutionarily conserved process where intracellular lipid and 
protein components are broken down to replenish cellular energy and amino acid 
supplies. Autophagy also removes protein aggregates, redundant macromolecules 
and dysfunctional organelles that, if not efficiently recycled, contribute to cell stress 
and consequently disease. Autophagy can play both pro- and anti-oncogenic roles in 
cancer development (Choi et al. 2013). Autophagy involves sequestering 
cytoplasmic material in double-membrane vesicles known as autophagosomes, 
which subsequently fuse with lysosomes to form autolysosomes. Once fusion 
occurs, lysosomal hydrolases degrade sequestered material allowing permeases to 
transport amino acids and lipids into the cytoplasm for use in either biosynthesis or 
the generation of energy (He & Klionsky 2009).   
Yeast screens uncovered over 30 autophagy-related (ATG) genes, many of 
which are recruited to the phagophore assembly site, a pre-autophagosomal 
membrane structure (Klionsky et al. 2011). Atg8 is conjugated to 
phosphatidylethanolamine (PE) and selectively incorporated into autophagosomes, 
making it a commonly used autophagy marker. Mammals have two ATG8 
subfamilies, the microtubule-associated protein 1 light chain 3 (MAP1LC3, commonly 
called LC3) subgroup and the ᵞ-aminobutyric acid receptor-associated protein 
(GABARAP)/Golgi-associated ATPase enhancer of 16 kDa (GATE-16) subfamily 
(Shpilka et al. 2011). Both mammalian ATG8 subfamilies are modified by PE 
conjugation, localise to autophagosomes and are essential for autophagy (Kabeya et 
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al. 2004). Current evidence indicates that LC3 and GABARAP act at different stages 
of autophagosome formation (Weidberg et al. 2010). 
ULK1 (the mammalian equivalent of Atg1) acts at the most upstream step of 
autophagy (Itakura & Mizushima 2010). ULK1 is a serine/threonine protein kinase 
that forms a complex with ATG13, FIP200 and ATG101, which drives formation of 
autophagosome (Hosokawa et al. 2009)(Mercer et al. 2009). This kinase complex is 
positively regulated by many internal ULK1-mediated phosphorylation events, 
including ULK1 autophosphorylation (Jung et al. 2009)(Ganley et al. 2009). 
Additionally, when  there is enough energy and nutrient for the cell, mTORC1 
promotes cell growth in part by inhibiting autophagy via phosphorylation of ULK1 
(Hosokawa et al. 2009)(Jung et al. 2009). Conversely, during energy and nutrient 
deprivation when it is not viable for the  cells to grow, AMPK interacts with and 
phosphorylates ULK1 to enhance autophagy (Kim et al. 2011).  
As mentioned in Chapter 1, mutations in FLCN are responsible for Birt-Hogg-
Dubé (BHD) syndrome which is characterised by benign hair follicle tumours, 
pneumothorax, pulmonary cysts and renal cancer (Nickerson et al. 2002).  
FLCN was recently shown to be a Rab GEF towards Rab35 (Nookala et al. 
2012). FLCN is a known downstream substrate of AMPK, where AMPK 
phosphorylates FLCN and FLCN interacting protein FNIP1 (Baba et al. 2006). FNIP1 
has recently been identified as an interactor of GABARAP (Behrends et al. 2010). 
BHD is also a ciliopathy and FLCN is localised at primary cilia (Luijten et al. 2013). 
Interestingly, a compromised ability to activate autophagy has been hypothesised to 
underlie some ciliopathies (Pampliega et al. 2013). Furthermore, FLCN was recently 
shown to localise to lysosomes and modulate nutrient sensing through the Rag small 
G proteins (Petit et al. 2013)( Tsun et al. 2013)(Martina et al. 2014). Given these 
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different possible links to autophagy, it was speculated that FLCN might play a 
fundamental role in autophagy. Hence the main aim of this result chapter was to 
determine whether FLCN might be involved in the regulation of autophagy. 
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3.2 Methods 
Cell Culture - It has been reported that kidney tumour in Flcn +/- mice initiated 
from renal proximal tubule cells (Hudon et al. 2010). Therefore, human renal 
proximal tubule (HK2) cells were utilised with stable FLCN knockdown as a model of 
BHD to explore renal pathology in this study. Stable FLCN knockdown in human 
kidney cells (HK2) was made by Dr. Tijs Claessens (Dr Andrew Tee’s laboratory, 
Cardiff University, UK). Flcn+/+ and -/- MEF cells were gifted by Prof. Arnim Pause 
(McGill University, Canada). All cell lines were cultured in DMEM supplemented with 
10 % (v/v) foetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin (Life 
Technologies). Lipofectamine® 2000 Reagent (Life Technologies) was used for 
transfection according to the manufacturer’s protocol. Cells were 70-90 % confluent 
at the time of transfection. Cells were harvested 24–36 h post-transfection. 
Experiments were performed under normal growth conditions, unless otherwise 
stated. For complete starvation, cells were washed twice in phosphate buffered 
saline (PBS) and incubated in Krebs Ringer buffer (KRB) (20 mM HEPES (pH 7.4), 
115 mM NaCl, 5 mM KCl, 10 mM NaHCO3, 2.5 mM MgCl2, 2.5 mM CaCl2) for 4 h. 
 
Immunoprecipitation, GST-pulldown and western blotting - Cells were lysed in 
BHD lysis buffer (20 mM Tris, 135 mM NaCl, 5 % (v/v) glycerol, 50 mM NaF and 0.1 
% (v/v) Triton X-100, pH 7.5 plus protease inhibitors), centrifuged and protein 
quantified using Bradford reagent (Sigma-Aldrich).  Anti-HA and anti-V5 coupled to 
Protein G-Sepharose beads (GE Healthcare Life Sciences) were used to 
immunoprecipitate HA and V5-tagged proteins as appropriate. Immunoprecipitates 
were washed three times in lysis buffer and resuspended in NuPAGE LDS sample 
buffer (Life Technologies). Samples for GST-pulldown were lysed in Buffer B (40 mM 
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HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM β-
glycerophosphate, 50 mM NaF, 1.5 mM Na3VO4, 0.3% (w/v) CHAPS plus protease 
inhibitors and incubated with glutathione-Sepharose beads (GE Healthcare Life 
Sciences). Beads were washed three times in lysis buffer, and GST-tagged proteins 
were eluted using 10 mM glutathione. Western blotting was performed as previously 
described. Blots shown are representative of at least three independent experiments. 
 
In vivo phosphate radiolabelling - Transfected HEK293 cells were incubated in 
phosphate-free medium containing 0.2 mCi [32P]-orthophosphate (PerkinElmer) for 
4 h. These cells were harvested using BHD lysis buffer. HA-FLCN was 
immunoprecipitated with anti-HA antibody bound to protein G-Dynabeads (Life 
Technologies) and washed in lysis buffer x3, prior to being suspended in x1 sample 
buffer and SDS-PAGE. 
 
Structural modelling - Crystal structure coordinates used in the current 
manuscript are as deposited in the protein data bank (PDB Id: 3V42). The model 
was generated using Pymol.  
 
Densitometry and statistical analysis - Densitometry was performed using 
ImageJ. v1.43 software. One way ANOVA followed by LSD post-hoc testing (as 
appropriate) was used for statistical analysis, with p < 0.05 taken to be significant. 
 
Protein alignment - Clustal Omega provided by The European Bioinformatics 
Institute (EMBL-EBI) was used for all multiple alignments. 
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3.3 Results 
 FLCN could possibly be involved in autophagy  3.3.1
p62 (also known as Sequestome1, SQSTM1) is a well-known marker of 
autophagy. As discussed in chapter 1, p62  is integrated to autophagosomes and 
gets degraded during autophagy (Pankiv et al. 2007). Of interest, p62 was shown to 
be over-expressed in renal cell carcinoma (Creighton et al. 2013). Over-expression 
of p62 could also be present in BHD patient RCC, since BHD syndrome predisposes 
patients to renal cell carcinoma. It was, therefore, important to analyse whether 
FLCN loss could enhance p62 protein levels. As expected, immunohistochemistry 
done by our collaborators in Maastricht revealed elevated p62 protein levels in a 
BHD patient renal tumour (with a c.499C>T mutation encoding a truncated FLCN 
mutant, pGln167X) when compared to unaffected tissue (Figure 3.1.A). 
Also when autophagy was induced in normal HK2 cells via starvation after 4 
h, FLCN mRNA level showed a significant increase (Figure 3.1.B). Similar up-
regulation of FLCN mRNA has been reported in starved Drosophila larvae (Erdi et al. 
2012), raising the possibility that FLCN might be involved in autophagy. 
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Figure 3.1 FLCN is likely involved in autophagy: (A) Immunohistochemistry of 
p62 (SQSTM1) indicates that p62 (SQSTM1) expression is higher in the renal 
tumour (T) from a BHD patient when compared to surrounding unaffected normal 
(N) renal tissue (IHC carried out by our collaborators (M.VanSteensel, Maastricht 
University)). (B) Relative levels of FLCN mRNA was determined from HK2 cells 
after 4 h of growth in DMEM with and without serum, as well as Krebs Ringer 
Buffer (lacking amino acids and glucose). Levels were standardised to β-actin. 
N=3, *** P < 0.001. 
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 Autophagy is down-regulated in FLCN-deficient cells 3.3.2
For reasons mentioned in the methods section HK2 cells were used in this 
study. p62 protein levels were shown to be elevated in FLCN-deficient HK2 cells 
when compared to control HK2 cells, which was significant in normal growth 
conditions. However under starvation condition where the cells were incubated in 
Krebs Ringer buffer for 4 h, although p62 protein level was still higher in FLCN-
deficient HK2 cells this elevation was not significant (Figure 3.2 A). This result could 
imply that FLCN may play a role in basal autophagy; however it could be expendable 
for more severe conditions such as starvation-induced autophagy. A similar pattern 
was also observed in Flcn-/- mouse embryonic fibroblasts (MEFs) (Figure 3.2 B).  
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Figure 3.2 Autophagy is down-regulated in FLCN-deficient cells: In both (A) 
HK2 cells and (B) MEF cells with and without loss of FLCN, p62 (SQSTM1) protein 
expression levels were determined in the presence or absence or starvation media 
(Krebs Ringer Buffer, lacking both amino acids and glucose). FLCN expression 
was determined to validate FLCN deficiency, and β-actin serves as a loading 
control. The relative levels of p62 (SQSTM1) was determined by densitometry and 
is graphed, N=3, * P < 0.05, *** P < 0.001.  
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 FLCN interacts with ULK1 3.3.3
Since AMPK and mTOR have both been shown to regulate autophagy 
through direct phosphorylation of ULK1 and, have also been linked to FLCN (Kim et 
al. 2011)(Baba et al. 2006), several experiments were designed to explore the 
relationship that FLCN might have in the regulation of autophagy and whether AMPK 
and/or mTOR was involved. Initially, interaction of ULK1 with FLCN was assessed. It 
was observed that immunoprecipitated V5-tagged ULK1 co-purified with FLCN 
(Figure 3.3A). In the same experiment a kinase dead mutant of ULK1 was also 
immunoprecipitated and FLCN-ULK1 interaction was shown to be more robust in the 
presence of inactive ULK1. To further characterise this novel interaction of FLCN 
with ULK1 with respect to BHD, a panel of BHD patient derived mutations were 
used. The C-terminal truncating mutations (Y463X and H429X) interacted more 
avidly with ULK1 than either wild-type FLCN or a BHD patient-derived point 
mutation, K508R (Figure 3.3B). This could suggest that the C-terminus of FLCN 
does not bind directly to ULK1 and may play a role in dissociation from ULK1.  
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Figure 3.3 FLCN interacts with ULK1: (A) Untagged FLCN was co-expressed with or without either V5-
tagged ULK1 wild-type or kinase dead (KD) in HEK293 cells. From generated cell lysates, V5 antibodies were 
used to immunoprecipitate V5-ULK1 and associated FLCN was determined by western blotting. Total lysates 
were analysed for total expression of both FLCN and V5-ULK1. (B) Similar to (A), but comparing interaction 
with HA-FLCN wildtype and 3 patient-derived mutations (K508R, Y463X and H429X). 
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 FLCN is an ULK1 substrate 3.3.4
Given that the kinase-dead form of ULK1 bound more strongly to FLCN, it is 
possible that FLCN could be a downstream substrate of ULK1. To explore whether 
FLCN was an ULK1 substrate, ULK1 kinase assays were carried out. HEK293 cells 
expressing HA-FLCN were radiolabelled by [³²P] in vivo and the [³²P] incorporation 
into HA-FLCN was determined in the presence or the absence of ULK1. The result 
shows that FLCN is phosphorylated by ULK1 in vivo (Figure 3.4A). This result 
combined with the FLCN-ULK1 interaction data above suggest that ULK1 is likely to 
bind to and phosphorylate FLCN in a transient manner rather than having a stable 
association. (The radioactive experiments were carried out by Dr. Andrew Tee, 
Cardiff University, UK) 
The cold samples were sent for mass spectrometry in Prof John Blenis Lab 
(Boston, Harvard Medical School), where three phosphorylation events were 
identified within the C-terminus of FLCN. These three sites (Ser406, Ser537 and 
Ser542), were unique to FLCN when co-expressed with wild-type ULK1 but not 
kinase dead ULK1 (Figure 3.4B and C). 
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Figure 3.4 FLCN is an ULK1 substrate: (A) HA-FLCN was immunoprecipitated 
from radiolabeled [32P]-orthophosphate labelled HEK293 cells with and without V5-
ULK1. Levels of HA-FLCN and radiolabeled [32P]-HA-FLCN are shown as well as 
expression levels of V5-ULK1. (B) Purified HA-FLCN from HEK293 cells expressing 
ULK1 or kinase dead ULK1, was analysed by MS-MS MALDI-TOF to identify protein 
phosphorylation events that were dependent on ULK1. Three unique ULK1-
dependent phosphorylation sites are shown (S406, S537 and S542) and are also 
represented in a cartoon representative of FLCN (C).  
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 ULK1 phosphorylates FLCN within a conserved C-terminus 3.3.5
A FLCN protein alignment between species was performed in clustal omega 
which showed that the identified phosphorylation sites on FLCN (Ser406, Ser537 
and Ser542) are quite conserved in vertebrates, particularly in mammals (Figure 
3.5). 
 
 
 
 
 
 
 
Figure 3.5 ULK1 phosphorylates FLCN at a conserved C-terminus: C-
terminal amino acid alignments spanning the regions where the three ULK1 
phosphoryation sites are shown. 
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 ULK1 phosphorylation sites within the C-terminus are shown to be on 3.3.6
the surface and are available for phosphorylation 
A structural model of FLCN showing the three best conserved ULK1-mediated 
phosphorylation sites of FLCN was generated from the recently determined C-
terminal structure of FLCN using PyMol (Figure 3.6), from the crystal structure [PDB 
Id: 3V42]. All three identified ULK1 phosphorylation sites are solvent exposed to the 
surrounding environment, making them accessible for phosphorylation.  
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Figure 3.6 Model structure of FLCN: The top middle figure shows the alpha 
helices and beta sheets structure of FLCN. Bottom left demonstrates the 
surface structure of the FLCN and bottom right the three ULK1 phosphorylation 
sites, in red, are shown to be on the surface, which are magnified at the top. 
 
. 
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 WT-FLCN rescues basal autophagy in FLCN deficient cells but not the 3.3.7
3A mutant 
To determine if it is actually the lack of FLCN that effects p62 protein level 
elevation, WT-FLCN was re-expressed in these FLCN-deficient HK2 cells together 
with HA- p62 to specifically measure autophagy in the transfected cells. As indicated 
by the marked reduction in p62, FLCN restored a higher level of autophagy in these 
cells (Figure 3.7). 
To test if the phosphorylation of FLCN by ULK1 plays a role in this rescue 
effect upon re-expression, a triple serine to alanine mutation of the ULK1 
phosphorylation sites on FLCN was made which from now on will be referred to as 
3A-FLCN (Figure 3.8.A). Both WT-FLCN and 3A-FLCN were over expressed in 
FLCN deficient HK2 cells together with HA-p62. It was observed that WT-FLCN over 
expression in FLCN-deficient HK2 cells reduces the expression levels of p62 protein, 
hence restores autophagy. Of interest, overexpression of 3A-FLCN did not rescue 
autophagy but rather impaired autophagy even further (Figure 3.8.B). Therefore, 
FLCN phosphorylation by ULK1 likely plays a positive role in autophagy.  
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Figure 3.7 Wild-type FLCN rescues basal autophagy 
in FLCN-deficient cells: HK2 cells that were stably 
transfected with shRNA towards FLCN or non-target 
control (NT), autophagy was rescued with HA-tagged 
FLCN re-expression where indicated. Total levels of p62 
(SQSTM1), FLCN and β-actin are shown. Denistometry 
analysis of p62 levels was carried out and is represented, 
N=3, *** P < 0.001. 
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Figure 3.8 3A mutant of FLCN does not rescue basal autophagy in 
FLCN-deficient cells: (A) Nucleotide sequence alignment of the 3A-FLCN 
mutant (where all three ULK1 phosphorylation sites have been mutated to 
alanines). (B) Either wild-type FLCN or 3A-FLCN mutant were expressed in 
HK2 cells that were stably expressing FLCN shRNA, where indicated. Total 
levels of FLCN, p62 (SQSTM1) and β-actin are shown. Denistometry 
analysis of p62 level was carried out and is represented, N=3, ** P < 0.01. 
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 GABARAP interacts with FLCN  3.3.8
The FLCN binding partner, FNIP1, was recently shown to interact with 
GABARAP (Behrends et al. 2010). GABARAP is mammalian orthologue of Atg8 with 
a potential role in regulating the sealing process needed for autophagosome 
maturation (Weidberg et al. 2010). Unbiased GABARAP interaction mass 
spectrometry was performed and eight high-confidence interacting proteins were 
identified, including both FNIP1 and FLCN (Figure 3.9A). To confirm this interaction 
FLCN and GABARAP were co-expressed in HEK293 cells in the presence or 
absence of FNIP1 or FNIP2. The same experiment was also set for LC3, which is 
another member of the ATG8 subfamily. It was observed that the 
immunoprecipitation of FLCN only co-precipitates GABARAP in the presence of 
FNIP2, but not LC3 (Figure 3.9B). However, the in vitro binding assay (done by Dr. 
Elaine Dunlop, Cardiff University, UK) could detect endogenous FLCN interaction 
with bacterially generated recombinant GABARAP and LC3 proteins, where there 
was a stronger interaction between GABARAP and FLCN. Taking into account both 
the in vitro and the in vivo results, it suggests the enhanced specificity of FLCN 
binding for GABARAP family members and that the over-expression of FNIP2 is 
necessary to strengthen this interaction. Overall, these data reveal that FLCN and its 
interacting partners FNIP1/2 affect the autophagy machinery through the interaction 
with GABARAP.  
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Figure 3.9 GABARAP interacts with FLCN, and this interaction is enhanced when co-
expressed with FNIP2: (A) GABARAP interactome is presented (carried out through 
collaboration with Christian Behrends, Goethe University Frankfurt). (B) Either HA-tagged 
LC3B or GABARAP was expressed in HEK293 cells in the presence of V5-FLCN with or 
without co-expression of either HA-FNIP1 or myc-FNIP2, where indicated. Anti-V5 
antibodies were used to immunoprecipitate V5-FLCN, and associated FNIP1, FNIP2 and 
GABARAP was determined by western blot analysis. Total blots of FLCN, LC3, GABARAP, 
FNIP1 and FNIP2 were also carried out. 
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 FLCN/GABARAP binding is impaired in BHD patient-derived mutants 3.3.9
Previous work in this study showed that BHD patient-derived mutants of 
FLCN bound more robustly with ULK1, suggesting the C-terminus of FLCN likely 
plays a role in dissociation of FLCN from ULK1. Therefore a similar experiment was 
set to compare the interaction of GABARAP with wild-type and BHD patient-derived 
mutants of FLCN. In contrast to ULK1 interaction, GABARAP interaction with FLCN 
was impaired in patient derived mutants (Figure 3.10). 
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Figure 3.10 FLCN-GABARAP binding is impaired in patient 
derived mutants: HA-GABARAP was co-expressed with either wild-
type FLCN, or FLCN mutant (K508R, Y463X, H429X) in HEK293 
cells. Anti-HA antibodies were used to immunoprecipitate HA-
GABARAP and associated FLCN was determined by western blot 
analysis. Total protein expression of FLCN and GABARAP is shown. 
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 FLCN interacts with Rab GTPases associated with autophagy 3.3.10
Previously Nookala et al. reported that FLCN functions as a GEF towards 
Rab35. Although interaction of Rab35 was observed with over-expressed FLCN in 
HK2 cells, no GEF activity could be detected in vitro (data not shown, (carried out by 
Dr. Andrew Tee, Cardiff University, UK)), suggesting that Rab35 might not be the 
bona fide small G-protein target of FLCN. Having seen the involvement of FLCN in 
autophagy, it was decided to study the interaction of FLCN with other candidate Rab 
small G-proteins previously linked to autophagy, i.e., Rab7, Rab24, Rab27b and 
Rab32. 
Although the interaction of FLCN with Rab7 and Rab27b was weaker than 
that of Rab24 and Rab32, over-expressed FLCN appeared to bind to all these 
autophagy-associated Rab small G-proteins to varying degrees (Figure 3.11). This 
supports the notion that FLCN may function upstream of several Rab small G-
proteins and likely regulates vesicular trafficking events linked to autophagy.  
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 Figure 3.11 FLCN interacts with autophagy associated Rab GTPases: 
Either Rab7, Rab24, Rab27b or Rab32 was expressed by itself or co-
expressed with GST-tagged FLCN, where indicated. GST-FLCN was 
purified on glutathione-Sepharose beads and associated Rab small G 
protein was assessed by western blot analysis. Total blots of FLCN and 
Rab small G-proteins are also shown. 
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 FLCN is not a typical GEF 3.3.11
To further investigate the GEF activity of FLCN towards the Rabs involved in 
autophagy, inactive mutants of Rab7 and Rab24 were made and their interaction 
was studied. To make the inactive Rab7 that cannot bind guanine nucleotide, 
aspartic acid 128 was mutated to asparagine and was called Rab7 D128N. To make 
the inactive Rab24 aspartic acid D123 was mutated to asparagine and was called 
Rab4 D123N. GST-tagged FLCN was over-expressed with either wild type or mutant 
Rab7/24 in HEK293 cells and after GST-pulldown, results were analysed. Since the 
mutant forms of these Rabs represent the GDP-bound state of the protein in their 
conformation, a more robust binding of FLCN to Rab mutants was expected if FLCN 
functioned as a GEF. However after several repeats the level of interaction differed 
between experiments. Figure 3.12 demonstrates one of the variable results where 
wild type Rabs were found to bind more avidly to FLCN than the inactive mutants. 
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Figure 3.12 FLCN is not a typical GEF: Either Rab7, Rab7 D128N, Rab24 or 
Rab24 D123N was expressed by itself or co-expressed with GST-tagged FLCN, 
where indicated. GST-FLCN was purified on glutathione-Sepharose beads and 
associated Rab small G protein was assessed by western blot analysis. Total 
blots of FLCN and Rab small G-proteins are also shown.  
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3.4 Discussion  
This chapter shows that FLCN interacts with and is a new downstream 
substrate of ULK1 and also that phosphorylation by ULK1 modulates the interaction 
of FLCN with both autophagy components, GABARAP and several Rab small G-
proteins linked to autophagy. These interactions with ULK1, GABARAP and Rab 
proteins link FLCN directly to the autophagy machinery and vesicular trafficking. It is 
also shown that FLCN plays a positive role in autophagy, where loss of FLCN leads 
to impaired autophagy. Furthermore, FLCN mutant lacking the ULK1-mediated C-
terminal phosphorylation sites could not restore autophagy in FLCN-deficient cells 
whereas the WT-FLCN could rescue autophagy. Of interest, LST7, the yeast 
homologue of FLCN, is required for transportation of the amino acid permease, 
Gap1p, from the Golgi to the cell surface (Roberg et al. 1997). This role of trafficking 
between cellular compartments in response to nutrients provides an evolutionary link 
to the proposed function of FLCN as an integral part of the autophagy machinery, 
probably co-ordinating vesicular trafficking through modulation of Rab activity. 
If FLCN functioned as a bona fide GEF, it was expected to have an enhanced 
binding to the non-guanine nucleotide binding mutants of Rabs. However, these Rab 
mutants sometimes bound less favourably with that of FLCN. Rab activators, GEFs, 
require a specific mechanism to target them to their site of action (Barr & Lambright 
2010). It is possible that the interaction between FLCN and GABARAP functions in 
an analogous manner to recruit FLCN to the autophagosomal membrane at the 
appropriate stage of the autophagic process. FLCN does not have a LIR motif; 
therefore its interaction with GABARAP/LC3 is an indirect interaction through the 
FNIPs. Although several attempts on FLCN GEF assays were made in our lab by Dr 
Andrew Tee it did not show any GEF activity for FLCN. It is likely that FLCN in a 
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complex with FNIP1 and FNIP2 could act as an atypical GAP/GEF (or even a Rab 
scaffold protein) that helps facilitate vesicular trafficking connected to autophagy.  
The binding partners of FLCN, FNIP1 and FNIP2, have previously been 
connected to B-cell development (Baba et al. 2012), autophagy via GABARAP 
(Behrends et al. 2010) and the induction of apoptosis following DNA-base mispairing 
(Lim et al. 2012). Here it is revealed that FNIP2 (and to a lesser extent FNIP1) 
enhances FLCN-GABARAP binding, implying that FLCN functions as a complex with 
FNIP proteins to regulate autophagy. GABARAP subfamily members appear to 
function downstream of autophagosome membrane elongation in a step coupled to 
dissociation of the Atg12-Atg5-Atg16L complex (Weidberg et al. 2010) and have 
been hypothesised to recruit and anchor the ULK1 complex on autophagosomes 
(Kraft et al. 2012) (Alemu et al. 2012).  
Although several key advances have been made in BHD syndrome research, 
such as the determination of an AMPK-FLCN interaction (Baba et al. 2006) and 
identification of a DENN domain (Nookala et al. 2012), the direct cellular function(s) 
of FLCN is still unknown. This work refines our understanding of FLCN, where FLCN 
is revealed to interact with several components integral to autophagy, namely ULK1, 
GABARAP, Rab7, Rab24 and Rab32. Although it is important to highlight that FLCN 
function is not just restricted to autophagy. Multiple pathways that drive cancer 
progression can become dysregulated when FLCN expression is lost, including 
defects in TGFβ-mediated signalling (S.-B. Hong et al. 2010)(Cash et al. 2011), 
enhanced hypoxia inducible factor activity (Preston et al. 2011) and TFE3 activity (S. 
B. Hong et al. 2010).  
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Recently, both p62 and FLCN have been linked to amino acid sensing 
through the Rag proteins and mTORC1. p62 was found to bind the Rag proteins to 
favour formation of the active Rag heterodimer, thereby helping activate mTORC1 at 
the lysosome (Duran et al. 2011). Although, no altered mTORC1 signalling following 
FLCN loss could be detected in our lab which could be due to cell type dependant 
activity of mTORC1 signalling in the context of FLCN-deficiency; three publications 
have now linked the FLCN/FNIP complex to the Rag small G proteins at the 
lysosome, linking FLCN to amino acid-dependent mTORC1 signalling (Petit et al. 
2013)(Tsun et al. 2013) (Martina et al. 2014).  
BHD syndrome has lately been reported to be a ciliopathy, where alteration to 
FLCN levels can cause changes to the onset of ciliogenesis (Luijten et al. 2013). 
Changes in FLCN levels are also associated with disruption of planar cell polarity 
and dysregulation of the canonical Wnt signalling pathway. Pampliega et al. 
suggested a compromised ability to activate the autophagic response as an 
underlying feature in some ciliopathies (Pampliega et al. 2013). Hence it is possible 
that there is also an association between cilia and autophagy in BHD syndrome, 
where impaired autophagy could be a contributing factor to ciliary defects and renal 
cyst formation in BHD syndrome patients. 
Overall this work helps refine our understanding of FLCN by revealing that 
FLCN interacts with components integral to autophagy, summarised in Figure 3.13,  
however, it is possible that FLCN could play a broader ‘housekeeping’ role in the cell 
and is likely to be a fundamental player in autophagy and cellular homeostasis 
outside the disease setting. Although further studies are required, it seems 
reasonable to assume that impaired autophagy upon loss of FLCN expression 
contributes in part to cancer progression in BHD patients. 
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Figure 3.14 Summary diagram, showing critical FLCN interacting proteins 
involved in autophagy and vesicular trafficking 
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4 Chapter 4: Familial multiple discoid fibroma (FMDF) 
4.1 Introduction 
In 2011 a series of families were studied by Starink et al. that presented a 
phenotype similar to BHD. However these families had no pathogenic FLCN 
germline mutations; furthermore none of these 9 families reported cases of renal cell 
carcinoma or recurrent pneumothorax. The onset of skin lesions was childhood or in 
early adulthood as oppose to BHD lesions that have a later onset in life usually 
occurring in the third decade. Starink et al. named this condition familial multiple 
discoid fibromas (FMDF, OMIM #190340) (Starink et al. 2012).  
BHD skin lesions mainly occur on the face and upper torso whereas the 
FMDF lesions were shown to generally appear on the ears. Familial trichodiscomas 
have a very similar clinical presentation to fibrofolliculomas but have two 
distinguishing features: they consist mostly of fibrous stroma and are of childhood 
onset. Additionally FMDF skin lesions histologically presented a hair follicle at their 
periphery as oppose to the fibrofolliculomas observed in BHD that often have a 
distorted hair follicle in the centre of the lesion (Starink et al. 2012).  
Another independent study also described two siblings aged 27 and 22 with 
dischoid fibromas; however they had no family history of skin, lung or renal 
abnormalities. The 27 year old man had multiple firm papules that had developed 
primarily over his face and ears, but also on his trunk and limbs since the age of 5 
years, whereas his 22 year old sister had an onset in adolescence. Same as in the 
Starink et al. study, no mutation in FLCN was found (Wee et al. 2013). 
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Wee et al. first treated the skin lesions with surgical procedures such as 
shave excision, hyfrecation and curettage and cautery; however the results were not 
satisfactory. Previously, it has been shown that rapamycin can improve the 
appearance of skin lesions in TSC (Haemel et al. 2010)(Mutizwa et al. 2011) hence 
Wee et al. treated the facial skin lesions of the affected 27 year old male with 
application of topical rapamycin at 1 mg/ml. After 8 weeks of treatment there was an 
evident improvement in the redness and size of the lesions (Wee et al. 2013). 
FMDF is an extremely rare genetic disorder and too little is known about the 
disease. Clinical symptoms, family and medical history play an important role in the 
diagnosis of the disease. However further research is required to better understand 
the pathogenesis and genes involved in FMDF to better aid the diagnosis and 
management of the condition. Therefore the main aim of this chapter was to further 
study FMDF. 
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4.2 Methods 
Segregation and haplotype analysis – (Carried out by our collaborators in 
Maastricht) Segregation analysis for the FNIP1 and FNIP2 loci was performed for 
families 11, 24, and 45 using polymorphic short tandem repeat markers distal and 
proximal to both genes. Short tandem repeat markers D4S2394, D4S1644, 
D4S1625, D4S413, D4S2997, D4S1090, D4S2368, D4S2431, D4S2417, D5S1453, 
D5S2501, D5S1505, D5S2098, D5S2120, D5S2057, D5S2002, D5S2117, D5S816, 
D5S1480, D5S820, and D5S1471 were amplified by standard procedures with one 
of the primers labelled with a fluorescent FAM (carboxyfluorescein) label. Fragment 
length was analysed on an ABI 3130 Genetic Analyzer (Applied Biosystems, Foster 
City, CA). Haplotype analysis was performed by analysing all available affected and 
unaffected family members using markers D5S1505, D5S2098, D5S2120, D5S2057, 
D5S2002, D5S2117, D5S816, and D5S1480 surrounding the FNIP1 locus. 
FNIP1 sequence analysis - (Carried out by our collaborators in Maastricht) 
Polymerase chain reaction (PCR) primers were designed to cover all 18 exons and 
exon/ intron boundaries of FNIP1. PCR products were sequenced using the 
BigDyeTerminator Cycle sequencing kit (Applied Biosystems) and an automated 
sequencer (ABI 3730 DNA analyzer). Sequencing data was analysed using Mutation 
Surveyor software (www.softgenetics.com) and by visual inspection. 
Primers: 
cloning FNIP1 fw: 5’TCTCGAGCTATGGCCCCTACGCTGTTCCAG3’ 
cloning FNIP1 rv: 5’CAGATCTTTAAAGGAGTATTTGTGCAAC3’ 
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site-directed mutagenesis fw:  
5'-TCTTAATTTATCTCTGTACTGTTTACATCAACAGCATTTTCTTCTTGG-3’ 
site-directed mutagenesis rv: 
5'-CCAAGAAGAAAATGCTGTTGATGTAAACAGTACAGAGATAAATTAAGA-3' 
Sequencing FNIP1 mutation: 5’CCACAACCATTCCTGTGGAT3’ 
Cell lines and cell culture - Primary skin fibroblasts with FNIP1 mutation were 
obtained from a skin biopsy taken from a consenting 27-year-old male subject 
diagnosed with FMDF (Carried out by our collaborators in Maastricht). All cells were 
cultured in DMEM supplemented with 10 % (v/v) foetal calf serum, 100 U/ml 
penicillin and 100 μg/ml streptomycin (Life Technologies). 
DNA constructs, transfections and antibodies - Human FNIP1 wild-type was 
amplified by PCR. FNIP1 mutant Val663fs were made by site-directed mutagenesis 
using the Quikchange II Site Directed Mutagenesis kit according to the 
manufacturer’s instructions (Agilent).  
Co-immunoprecipitation and Western blotting - HEK293 cells transiently 
transfected with appropriate plasmids were lysed in BHD lysis buffer (20 mM Tris, 
135 mM NaCl, 5% (v/v) glycerol, 50 mM NaF and 0.1% (v/v) Triton X-100, pH 7.5 
supplemented with protease inhibitors), centrifuged and protein quantified using 
Bradford reagent (Sigma-Aldrich). Anti-HA and anti-V5 coupled to Protein G-
Sepharose beads (GE Healthcare Life Sciences) were used to immunoprecipitate 
HA- and V5-tagged proteins as appropriate. Immunoprecipitates were washed three 
times in lysis buffer and resuspended in NuPAGE LDS sample buffer (Life 
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Technologies). Western blotting was performed as previously described. Blots 
shown are representative of at least three independent experiments. 
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4.3 Results 
 Families with FMDF have common ancestors and affected members 4.3.1
have FNIP1 c.1989delT mutation 
Eight out of nine families in this study (same families as the Starink et al. 
study) originate from the same Dutch village, which forms a small ethnic isolate. 
Genealogical studies confirmed common ancestry of these families, suggesting a 
founder effect (Figure 4.2). Clinical re-evaluation with a specific focus on lungs and 
kidneys again did not reveal any systemic abnormalities. Consequently, co-
segregation of FMDF with the FNIP1 locus in nine Dutch families was found, while 
excluding FNIP2. In these families, all available FMDF cases (n=27) carried a 
heterozygous germline mutation in FNIP1 (c.1989delT), which was not present in 
any of the unaffected family members.  
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Figure 4.2 Families with FMDF have common ancestors and 
affected members have FNIP1 c.1989delT mutation: Pedigree 
showing the relation between FMDF kindreds identified on the Island of 
Urk. Linkage analysis confirmed common ancestry for all FMDF patients 
with the FNIP1 c.1989delT mutation. 
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 The c.1989delT mutation predicts the frameshift p.Val663fsX which is a 4.3.2
conserved residue in vertebrates 
FNIP1 is an evolutionary conserved protein especially at the C-terminus 
(Figure 4.3 A). The c.1989delT mutation found in FMDF families causes a frameshift 
at valine 663 (p.Val663fsX) which leads to a C-terminal deletion. valine 663 is also 
an evolutionary conserved residue (Figure 4.3 B).  
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Figure 4.3 FNIP1 protein alignment: FNIP1 is a highly conserved protein across 
species especially at the C-terminus (A) valine 663 which is mutated in FMDF 
families, is an evolutionary conserved residue (B)  
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 FLCN/FNIP1 interaction is impaired by c.1989delT mutation 4.3.3
FNIP1 is a poorly studied protein and its function is not fully understood. 
FNIP1 has been reported to interact with FLCN where deletion of the 237 C-terminal 
amino acids of FNIP1 was shown to result in decreased FLCN binding (Baba et al. 
2006). Accordingly, using co-immunoprecipitation the interaction of endogenous 
FLCN with both wild type FNIP1 and FNIP1-Val663fsX was studied. FLCN 
interaction with FNIP1-Val663fsX was shown to be completely abolished (Figure 
4.4), which was expected according to the Baba et.al. study. However, in a 
reciprocal experiment where overexpressed FLCN was immunoprecipitated, only 
partial impairment of FNIP1-Val663fsX interaction with FLCN was observed (Figure 
4.5). This could be explained if FNIP1-Val663fsX was interacting with FLCN via 
FNIP2. 
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Figure 4.4 FLCN/FNIP1 interaction is impaired by c.1989delT mutation: HA-
FNIP1 (wild-type and Val663fsX6) was expressed in HEK293 cells. HA antibody was 
used to immunoprecipitate both HA-FNIP1 and HA-ΔFNIP1 in generated cell lysates. 
Associated endogenous FLCN was determined by western blotting, showing 
decreased binding of endogenous FLCN to FNIP1-Val663fsX6 (ΔFNIP1) compared to 
FNIP1 wild-type.  
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Figure 4.5 FLCN/FNIP1 interaction is impaired by c.1989delT mutation: HA-
FNIP1 (wild-type and Val663fsX6) was expressed in HEK293 cells with or without V5-
FLCN. V5 antibody was used to immunoprecipitate FLCN in generated cell lysates. 
Decreased binding of ΔFNIP1 compared to FNIP1 wild-type can be observed. 
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 FNIP1/FNIP2 interaction is not modified by c.1989delT mutation 4.3.4
Previously it has been shown that deletion of all of the five conserved 
domains of FNIP1 is necessary to abolish FNIP2 binding (Hasumi et al. 2008). To 
test if the interaction of FNIP1 with FNIP2 is affected in FMDF families, wild-type 
FNIP1 and Val663fsX6 FNIP1 was over-expressed in HEK293 cells with or without 
myc-FNIP2. From the generated cell lysate either FNIP1 (Figure 4.6 A) or FNIP2 
(Figure 4.6 B) was immunoprecipitated. It was observed that both wild-type and 
mutant FNIP1 interact with FNIP2. 
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Figure 4.6 FNIP1/FNIP2 interaction is not modified by c.1989delT mutation: 
wild-type FNIP1 and Val663fsX6 FNIP1 were over-expressed in HEK293 cells 
with or without myc-FNIP2. Either HA immunoprecipitation (A) or Myc 
immunoprecipitation (B) was performed on the cell lysate generated (C). 
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4.4 Discussion  
Although the clinical presentation of the fibrofolliculomas and discoid fibromas 
is similar, histologically they are distinct. In addition, none of the FMDF patients show 
any extracutaneous manifestations, suggesting that FNIP1 is only critical in the skin. 
Of interest, FNIP1 has been reported to be expressed at low levels in the lung and 
kidney, while FNIP2 is expressed at higher levels in these organs (Takagi et al. 
2008)(Hasumi et al. 2008). In other tissues, loss of FNIP1 might be tolerated, or the 
mutant protein might be expressed at higher levels than in the skin tissue. These 
observations suggest of differing functions for FLCN and FNIP1; this is further 
supported by the high degree of variation in phenotype observed with FLCN and 
FNIP1 mutations in humans. FNIP1 Val663fsX has impaired binding to FLCN, but 
not to FNIP2 and therefore might maintain partial functionality. Alternatively lack of 
systemic phenotype could be explained by compensation through FNIP2.  
Collectively these findings represent the first human disorder caused by a 
mutation in one of the folliculin interacting proteins, with a phenotype distinct from 
BHD. Whether the FNIP1 mutation in these patients would function in a similar 
regard to that of BHD patient mutations within the FLCN-deficient cells is doubtful.  
To determine if FNIP1-Val663fsX6 is expressed or broken down by nonsense 
mediated mRNA decay, fibroblasts were obtained from discoid fibroma biopsy 
material by our collaborators in Maastricht. Genomic sequencing of the FNIP1 locus 
confirmed presence of heterozygous c.1989delT; no somatic second hits were 
detected. Sequencing of cDNA from these fibroblasts showed minimal presence of 
mutant mRNA, which increased after incubation with puromycin (an inhibitor of 
nonsense-mediated mRNA decay). In addition, no wild-type or Val663fsX6 FNIP1 
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was detected by Western blot in these cells (data not shown). Together, these data 
indicate that FMDF could be caused by FNIP1 haploinsufficiency.  
However, recently Prof Julian Sampson and his group were presented with a 
family consisting of four members, with a germline whole gene deletion of FNIP1 in 
addition to loss of the 5’ region of RAPGEF6 encompassing exon 1, and the 3’ 
region of LOC728637, encompassing the last 4 exons (exon 9-12). In contrast to the 
FMDF patients, this FNIP1 deletion, does not give rise to the characteristic of discoid 
fibromas that are associated with a FNIP1 single base-pair deletion in FMDF 
(unpublished data). Therefore, it is less likely that the disease is caused by 
haploinsufficienciency of FNIP1. 
Given that loss of FNIP1 in these patients does not appear to result in cancer, 
there is possible redundancy between FNIP1 and FNIP2. To further study and 
compare the cellular function of FNIP1 and FNIP2, FNIP1 and FNIP2 knockdown 
cells were created in Chapter 5. 
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5 Chapter 5: Characterising FNIP1, FNIP2 and FLCN interactions 
5.1 Introduction 
Very little is known about FLCN interacting proteins, FNIP1 and FNIP2. FNIP2 
was the first of the two interacting proteins to be identified. Nagase et al., in a study 
of human cDNA library identified the FNIP2 gene, which was then designated 
KIAA1450 (Nagase et al. 1998). However it wasn’t until 2008 that Hasumi et al. 
identified it as FLCN interacting protein 2 (Hasumi et al. 2008).   
FNIP1 was first identified by Baba et al. 2006 where they showed that it 
interacts directly with FLCN and also facilitates phosphorylation of FLCN by AMPK. 
Baba et al., also demonstrated that FNIP1 binds to AMPK and that both FLCN and 
FNIP1 are phosphorylated by AMPK (Baba et al. 2006). Furthermore FLCN/FNIP1 
interaction has been shown to be altered by treatment of AMPK inhibitor (compound 
C), and also with rapamycin and amino acid starvation (Baba et al. 2006). Other 
post-translational modification of FNIP1 published to date include phosphorylation by 
mTOR (Yu et al. 2011) and ubiquitination at lysine 161 (Wagner et al. 2011). 
Both FLCN interacting proteins, FNIP1 and FNIP2, have been shown to be 
essential for recruitment of FLCN to the lysosomes during amino acid starvation, it 
has also been demonstrated that FNIP1 and FNIP2 are required for interaction 
between FLCN and the Rag small G proteins facilitating the activation of Rags by 
FLCN (Petit et al. 2013)(Tsun et al. 2013). 
FNIP1 has been linked to B cell development in mice by two independent 
studies published in 2012 (Park et al. 2012)(Baba et al. 2012). Park et al. found 
dysregulation of both AMPK and mTOR activity in FNIP1-null pre-B cells, which 
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resulted in excessive cell growth and enhanced sensitivity to apoptosis. 
Consequently they suggested that energy stress as a result of FNIP1 loss is the 
cause of B cell arrest  (Park et al. 2012). In contrast the FNIP1-null mice generated 
by Baba et al. did not demonstrate any alterations in mTOR activity. However they 
also observed a substantial increase in apoptosis, hence suggesting that a caspase 
induced pre-B cell death as the cause of defects in B cell development in FNIP1-null 
mice (Baba et al. 2012). 
In the follow-up study Park et al. demonstrated that invariant Natural Killer T 
(iNKT) cells do not develop to full maturation in FNIP1-null mice either. FACS 
analysis of the iNKTs from the FNIP1-null mice in this study revealed that stage 1 
and stage 2 iNKT cells are present whereas very few stage 3 iNKT cells could be 
found. This finding suggests that the maturation of these cells in the absence of 
FNIP1 is blocked between stage 2 and stage 3. There was also a significant 
increase in caspase 3-positive cells in stage 2 and stage 3 iNKTs. mTOR activity in 
FNIP1-null iNKT cells was shown to be increased and the number of mitochondria to 
be decreased despite the low ATP levels. These results could suggest that FNIP1 
plays an important role development of iNKTs by regulating their metabolic 
homeostasis (Park et al. 2014). 
In a mega proteomic study of the human autophagy network in 2010 
Behrends et al. found FNIP1 to interact with GABARAP (Behrends et al. 2010).  
GABARAP together with LC3 and GATE16 are the human orthologs of ATG8 family 
of proteins that are crucial for autophagosome formation (Shpilka et al. 2011). 
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In 2012 it was revealed that FNIP1 and FNIP2, both contain a DENN domain, 
similar to FLCN, implicating them in membrane trafficking which could be during 
various stages of autophagy (Zhang et al. 2012).   
One of the earliest pathways that FNIP2 was reported to be involved in was 
O6-methylguanine triggered apoptosis (Komori et al. 2009). Further studies revealed 
that upon treatment with N-methyl-Nnitrosourea (MNU) FNIP2 levels in the cells 
increased due to stabilisation of the FNIP2 protein, since mRNA level was not 
changed (Lim et al. 2012)(Sano et al. 2013). 
The most diverse role suggested for FNIP2 is its requirement for myelination 
in the central nervous system (Pemberton et al. 2014). In Pemberton et al. study the 
Weimaraner dog was found to have a frameshift mutation in FNIP2 gene which 
resulted in a C-terminal truncation of the protein. This truncated FNIP2 protein was 
shown to cause hypomyelination of the brain and myelin defects in the spinal cord. It 
was also demonstrated that FNIP2 expression in oligodendrocytes was regulated by 
the transcription factor Sox10 (Pemberton et al. 2014). 
Two independent studies have shown that similar to FNIP1, FNIP2 also binds 
to and is phosphorylated directly by AMPK (Hasumi et al. 2008)(Takagi et al. 2008). 
FNIP1 and FNIP2 are homologous proteins that have been shown to be able to form 
both homodimers and hetrodimers (Takagi et al. 2008). 
It has been published that both FLCN interacting partners FNIP1 and FNIP2 
interact with FLCN through its C-terminal (Baba et al. 2006)(Hasumi et al. 
2008)(Takagi et al. 2008). Of interest, most of the disease causing mutations in BHD 
syndrome produce a C-terminal truncated form of FLCN (Schmidt et al. 2005). It is 
not known if the truncated form of FLCN is left within the cell with defective function 
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or it undergoes nonsense-mediated decay, however the latter is less likely to be true 
as deletion of the whole FLCN gene, which is observed in Smith-Magenis syndrome 
(SMS) (OMIM182290), does not produce any of the BHD symptoms (Bi et al. 2002). 
SMS is a congenital disorder caused by a mutation in the RAI1 gene; though the 
majority of the patients lose this gene by a heterozygous deletion of part of 
chromosome locus 17p11.2 (Bi et al. 2002). This region includes the FLCN gene, 
which leaves these patients with only one wild-type FLCN allele. The absence of any 
obvious BHD associated symptoms in SMS patients would suggest that the 
presence of a mutant FLCN allele is required for BHD symptoms to develop. Whilst 
the mechanism driving tumourigenesis in BHD remains unclear, it is apparent that 
the majority of disease causing mutations result from C-terminus truncations to the 
FLCN protein. These truncated proteins are unable to interact with both FNIP1 and 
FNIP2, suggesting that this FLCN: FNIP1/FNIP2 interaction could be of functional 
significance within cells. There could also be other unknown C-terminus interactors 
which have yet to be discovered.  
Since FNIP1 and FNIP2 and their interaction with FLCN seems to be vital for 
the normal physiology of the cell, the main aim of this result chapter was to further 
study the role of FNIP1 and FNIP2 within cells.  
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5.2 Methods 
Cell culture - All cell lines were cultured in DMEM supplemented with 10 % 
(v/v) foetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin (Life 
Technologies).  
Transfection - Lipofectamine® 2000 Reagent (Life Technologies) was used for 
transfection according to the manufacturer’s protocol. Cells were 70-90 % confluent 
at the time of transfection. Cells were harvested 24–36 h post-transfection. 
Experiments were performed under normal growth conditions, unless otherwise 
stated. For complete starvation, cells were washed twice in phosphate buffered 
saline (PBS) and incubated in Krebs Ringer buffer (KRB) (20 mM HEPES (pH 7.4), 
115 mM NaCl, 5 mM KCl, 10 mM NaHCO3, 2.5 mM MgCl2, 2.5 mM CaCl2) for 4 h. 
Since a large number of cells needed to be transfected for GST purification, CaCl2 
transfection was used. DNA complexes were prepared by combining the DNA with 
ddH2O, CaCl2 was then added and the solution was vortexed. BES solution was then 
slowly added drop-wise whilst aerating the sample with a drawn glass pasteur 
pipette. Mixtures were left to stand at room temperature for 15-20 min (until 
precipitate becomes visible) then added drop-wise to the cells. 
MISSION shRNAs to knockdown each FNIP1 and FNIP2 were purchased from 
Sigma Aldrich as follows: 
FNIP1:  
pLKO.1puro-shRNA0369 
pLKO.1puro-shRNA9563 
pLKO.1puro-shRNA9412 
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pLKO.1puro-shRNA9414 
pLKO.1puro-shRNA9515 
FNIP2: 
pLKO.1puro-shRNA5772 
pLKO.1puro-shRNA5784 
pLKO.1puro-shRNA6305 
pLKO.1puro-shRNA6306 
pLKO.1puro-shRNA6307 
Immunoprecipitation, GST-pulldown, western blotting - Cells were lysed in 
BHD lysis buffer (20 mM Tris, 135 mM NaCl, 5 % (v/v) glycerol, 50 mM NaF and 0.1 
% (v/v) Triton X-100, pH 7.5 plus protease inhibitors), centrifuged and protein levels 
standardised using a Bradford assay (Sigma-Aldrich).  Anti-HA and anti-Flag coupled 
to Protein G-Sepharose beads (GE Healthcare Life Sciences) were used to 
immunoprecipitate HA and Flag-tagged proteins as appropriate. Immunoprecipitates 
were washed three times in lysis buffer and resuspended in NuPAGE LDS sample 
buffer (Life Technologies). Samples for GST-pulldown were lysed in Buffer B (40 mM 
HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM β-
glycerophosphate, 50 mM NaF, 1.5 mM Na3VO4, 0.3% (w/v) CHAPS plus protease 
inhibitors) and incubated with glutathione-Sepharose beads (GE Healthcare Life 
Sciences). Beads were washed three times in lysis buffer, and GST-tagged proteins 
were eluted using 10 mM glutathione. Western blotting was performed as previously 
described. Blots shown are representative of at least three independent experiments. 
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Mass spectrometry - GST-FLCN, GST-FNIP1 and GST-FNIP2 were purified from 
HEK293 cells. Samples were separated by SDS-PAGE and excised bands were 
subjected to mass spectrometry in collaboration with Dr Bryan Balliff (Vermount 
University). 
RNA extraction, qPCR - cells were lysed in RNA protect Cell Reagent and 
centrifuged at 5000 rpm for 5 min, the pellet was saved for mRNA extraction.  mRNA 
was extracted using the Qiagen mRNA extraction kit in accordance with 
manufacturer’s protocol, QIA shredders (QIAGEN) were utilised to homogenise the 
pellet. Resulting mRNA concentration was determined using the nanodrop 
spectrophotometer. cDNA was prepared using the QIAGEN reverse transcription kit 
according to the manufacturer’s protocol. Quantitative real-time PCR reactions were 
performed in 96-well plates using appropriate primers and Sybr Green PCR Master 
mix (QIAGEN). All primers were purchased from QIAGEN as follows: 
Hs_FLCN_1_SG QuantiTect Primer Assay, cat no: QT00088417 
Hs_FNIP1_1_SG QuantiTect Primer Assay, cat no: QT01029063 
Hs_FNIP2_1_SG QuantiTect Primer Assay, cat no: QT01672629 
Hs_GABARAP_1_SG QuantiTect Primer Assay, cat no: QT00203532 
Hs_SQSTM1_1_SG QuantiTect Primer Assay, cat no: QT00095676 
Protein alignment - Clustal Omega provided by The European Bioinformatics 
Institute (EMBL-EBI) was used for all multiple alignments. 
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5.3 Results  
 Generation of FNIP1 and FNIP2 stable knockdown cell lines 5.3.1
To characterise and better understand the role of FLCN interacting proteins, 
two stable knockdown cell lines were generated using both FNIP1 and FNIP2 
shRNAs. To make an efficient knockdown cell line, first a series of five different 
FNIP1 and FNIP2 shRNAs were transiently transfected into HEK293 cells to 
determine which of these shRNAs were most effective. The cells were harvested 
after 48 h and RNA was extracted from the cells. qPCR was carried out and the two 
shRNAs which demonstrated the best knock down for each FNIP (Figure 5.1A,B), 
were selected to generate the stable FNIP1 and FNIP2 knockdown cell lines. 
For reasons previously described in chapter 3, HK2 cells were used to 
generate FNIP1 and FNIP2 stable knockdown cell lines. HK2 cells were transfected 
with both selected shRNA plasmids (sh9563 and sh9412 for FNIP1, sh5784 and 
sh6305 for FNIP2) and after 48 h the selection media containing 2µg/mL of 
puromycin, was added to the cells. Subsequently 16 clones from each knockdown 
were isolated to grow. After 2-3 month the clones that had survived were selected.  
Gene expression levels of FNIP1 and FNIP2 mRNAs were examined in all selected 
clones to ensure the efficiency of knockdown (Figure 5.2A,B). 
FNIP1 clones A8 and B2 had 82% and 85% knockdown, respectively (Figure 
5.2A), while FNIP2 clones A6 and B5 had 88% and 83% (Figure 5.2B). These cell 
lines with the most effective knockdown were used for further experiments.   
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Figure 5.1 Transient knockdown of HEK293 cells with FNIP shRNAs: 5 different shRNA vectors targeting either FNIP1 or 
FNIP2, with non-target shRNA as a control were transiently transfected into HEK293 cells to test for efficiency of knockdown. 
mRNA extracted was analysed by Q-PCR to determine relative levels of either (A) FNIP1 or (B) FNIP2 expression, which was 
standardised against β-actin. N = 3. *** P < 0.001. 
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Figure 5.2 Stable knockdown of HK2 cells with FNIP shRNAs: Stable cell lines 
expressing either (A) FNIP1 or (B) FNIP2 selected shRNAs were created and 
validated for efficient knockdown after selection. mRNA extracted was analysed by Q-
PCR to determine relative levels of either FNIP1 or FNIP2 , where indicated, which 
was standardised against β-actin. N = 3. *** P < 0.001. 
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 Early morphological changes were observed in FNIP1 stable knockdown 5.3.2
cell lines  
During the first few weeks after the knockdown of FNIP1 in the HK2 cells, 
many FNIP1 shRNA expressing cells underwent a drastic morphological change 
(Figure 5.3A) compared to the normal HK2 cells expressing non-target shRNA 
(Figure 5.3B). The growth of these FNIP1 knockdown cells was dramatically reduced 
and the cells appeared expanded and full of fatty acid deposits. Also quite a few 
ghosts cells were observed, where these cells had likely ruptured leaving membrane 
structures (Figure 5.3A). The accumulation of fatty acid deposits in the cells could be 
an indication of FNIP1’s involvement in metabolic pathways such as lipolysis 
/lipogenesis. However after a couple of months of selection the growth rate returned 
to a level equivalent to the control HK2 cell lines, and the morphological changes 
were abolished. This suggests the existence of compensatory signalling 
mechanisms within these cells in order to overcome the lack of FNIP1. It is likely that 
the slow growing cells were undergoing a level of crisis, and/or homeostatic 
imbalance that was rectified through a low level of FNIP1 re-expression. Indeed, 
complete loss of FNIP1 expression was not observed. 
Although the FNIP2 knockdown cells also grew slowly initially, unlike the FNIP1 
knockdowns they did not demonstrate obvious morphological changes. However 
some minor changes could be observed including spiky cytoplasmic projections 
(Figure 5.4A), compared to control HK2 cells (Figure 5.4B). It is possible that these 
cytoplasmic projections are as a result of incomplete cell division which in turn could 
indicate the involvement of FNIP2 in cytokinesis. 
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Figure 5.3 Early 
morphological changes 
were observed in FNIP1 
stable knockdown cell 
lines: Phase contrast 
images (x40) of clonal 
populations were taken 
during the selection of 
HK2 cells that were 
transfected with FNIP1 
double shRNA, where (A) 
shows cells that are 
enlarged and appear to 
be undergoing cellular 
crisis and (B) control HK2 
cells expressing non-
target shRNA. 
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Figure 5.4 Minor 
morphological changes 
were observed in FNIP2 
stable knockdown cell 
lines: Phase contrast 
images (x40) of clonal 
populations were taken 
during the selection of 
HK2 cells that were 
transfected with FNIP2 
double shRNA. (A) 
Images highlight minor 
morphological changes 
while clonal expansion of 
cells taken within (B) 
control HK2 cells 
expressing non-target 
shRNA. 
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 When FNIP2 is knocked down, other components of the complex, i.e., 5.3.3
FLCN and FNIP1 were observed to be present at higher levels in the cell   
To characterise the FNIP1/2 stable knockdown cell lines, the initial step was 
to closely study the components of the FLCN/FNIP complex. Unfortunately a specific 
working FNIP2 antibody suitable for western blotting could not be obtained, therefore 
only FLCN and FNIP1 protein levels were examined. Figure 5.5A reveals a 
significant level of FNIP1 protein knockdown was achieved in these stable 
knockdown cell lines (Figure 5.5A). The results clearly demonstrate that in the FNIP2 
knockdown cells, FNIP1 protein levels were significantly higher compared to control 
HK2 cells (Figure 5.5B). FLCN protein levels were also observed at higher levels in 
FNIP2 knockdown cell lines, showing up to 2.6 fold higher in clone A6 (Figure 5.5D). 
However FNIP1 knockdown cell lines did not show any significant change in FLCN 
protein levels (Figure 5.5C).  
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Figure 5.5 Loss of FNIP2 expression is compensated by enhanced 
expression of FNIP1 and FLCN: Clonal cell lines for (A) FNIP1 (clones A8 
and B2) and (B) FNIP2 (clones A6 and B5) knockdown were analysed for 
expression of FNIP1 protein by western blot analysis and were compared to 
non-target control HK2 cells. Total FLCN expression within these (C) FNIP1 
and (D) FNIP2 clones were also determined. (E-F) β-Actin was used a loading 
control. Densitometry was carried out to determine relative protein levels 
between samples and is graphed. N = 3, * P < 0.05, *** P < 0.001. 
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 FNIP1 and FNIP2 both possess conserved LIR motifs 5.3.4
Both FNIP1 and FNIP2 are highly conserved across species (Figure 5.6A-C). 
Of interest, in less developed species like worms and flies, there is only one FNIP 
protein. Although the worm/fly FNIP shows homology to both human FNIP1 and 
FNIP2, it is more closely related to the FNIP2 protein (Hasumi et al. 2008). 
Correspondingly, both proteins contain a LIR motif. Figure 5.6D demonstrates known 
classic LIR motifs amino acid sequences. The LIR motif in FNIP2 is the classic F-
type, which is an evolutionary conserved LIR motif; whereas FNIP1 has a partial LIR 
motif (Figure 5.6A). The F-type LIR motifs are known to have a higher affinity to bind 
the GABARAP subfamily of Atg8s (Alemu et al. 2012). This could be the reason why 
the presence of FNIP2 is necessary for GABARAP/ FLCN interaction demonstrated 
in chapter 3, while FNIP1 had less of an impact. 
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Figure 5.6 FNIP1 and FNIP2 are highly conserved proteins across species and 
both contain a LIR motif: Amino acid alignments of the potential LIR motif 
comparing (A) human FNIP1 and FNIP2, either (B) FNIP2 or (C) FNIP1 between 
species as indicated, and a (D) classic consensus sequence of a LIR motif are 
shown. 
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 Starvation of HK2 cells induces FNIP1 and FNIP2 expression  5.3.5
It was shown earlier that FLCN mRNA expression was significantly higher 
upon induction of autophagy via nutrient and energy starvation. To see whether or 
not the FNIP proteins are also involved in autophagy, HK2 cells were cultured under 
three different conditions, normal DMEM, serum free DMEM and Krebs Ringer buffer 
(lacking both amino acids and glucose). The cells were harvested after 24 hours and 
mRNA was extracted from the cells. Both FNIP1 and FNIP2 mRNA levels showed a 
significant increase upon serum starvation compared to normal growth conditions 
(Figure 5.7), this was further increased with amino acid/glucose starvation.  
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Figure 5.7 Glucose and amino acid starvation causes higher gene 
expression of FNIP1 and FNIP2 within normal HK2 cells: HK2 cells 
were grown in the presence of either DMEM with and without serum, or 
Krebs Ringer Buffer (without amino acids and glucose), where indicated. 
mRNA extracted was assessed for either (A) FNIP1 mRNA or (B) FNIP2 
mRNA by Q-PCR to determine relative gene expression that was 
standardised to β-actin. N = 3, *** P < 0.001. 
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 FNIP2 knockdown shows similar molecular defect characteristic to 5.3.6
FLCN knockdown cells 
It was shown in chapter 3 that autophagy is down regulated in FLCN deficient 
cells. Evidence suggests that FNIP1 and FNIP2 may also play a role in autophagy, 
given that both FNIP1 and FNIP2 contain a conserved LIR motif, FNIP1 interacts 
directly with GABARAP. Additionally both FNIP1 and FNIP2 gene expression levels 
were higher upon starvation induced autophagy. Therefore autophagy was studied in 
FNIP1/2 deficient cells by measuring GABARAP and p62 protein levels in these cell 
lines. Both GABARAP and p62 protein levels were observed to be significantly 
higher in FNIP2 knockdown cells (Figure 5.8B,D) whereas no significant results were 
observed for FNIP1 knockdown cells (Figure 5.8A,C). p62 protein levels in FNIP1 
knockdown cells were inconsistent after several repeats. GABARAP levels appeared 
to increase, however these results were not significant. Collectively, these results 
indicate that FNIP2 might play a more critical role in the regulation of autophagy 
when complexed with FLCN.  
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Figure 5.8 FNIP2 knockdown causes autophagy defects similar to FLCN 
knockdown: Both FNIP1 knockdown HK2 clones (A8 and B2) and FNIP2 (clones 
A6 and B5) were assessed for (A-B) p62 (SQSTM1) and (C-D) GABARAP, 
expression, respectively. Non-target shRNA expressing HK2 cells were used as a 
control. Densitometry was carried out to determine relative protein levels between 
samples and is graphed. N = 3, * P < 0.05, *** P < 0.001. 
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 FNIP knockdown alters expression of selected autophagy proteins  5.3.7
To find out if the differences seen in protein levels within FNIP knockdown cell 
lines were as a result of transcriptional changes, gene expression levels were 
examined by measuring mRNA levels in these cell lines. Although FNIP1 protein 
levels were significantly higher in FNIP2 deficient cells, FNIP1 gene expression was 
not significantly different compared to control HK2 cells (Figure 5.9A). In contrast, 
FNIP2 mRNA expression was shown to be significantly higher in FNIP1 deficient 
cells (Figure 5.9B). In line with protein level analysis of FLCN in FNIP knockdown 
cell lines, FLCN gene expression was shown to be significantly higher in FNIP2 
deficient cells but not in FNIP1 deficient cells (Figure 5.9C). GABARAP gene 
expression also mirrored the protein levels, where the expression level was 
significantly higher in FNIP2 deficient cells but no significant change was observed in 
FNIP1 deficient cells (Figure 5.9D).  
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Figure 5.9 Gene expression levels on the FNIP knockdowns: mRNA 
expression levels of (A) FNIP1, (B) FNIP2, (C) FLCN and (D) GABARAP were 
assessed in both a FNIP1 (HK2 FNIP1 shRNA clone A8) and FNIP2 (HK2 FNIP2 
shRNA clone B5) with non-target shRNA HK2 cells used as a control. N = 3, * P < 
0.05, ** P < 0.01, *** P < 0.001 
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 GST purification of FLCN, FNIP1 and FNIP2  5.3.8
Very little is known regarding protein interactions of FLCN, FNIP1 and FNIP2. 
Therefore, to study protein associations with FLCN/FNIPs in an unbiased manner, 
mass spectrometry was performed on samples enriched for FLCN, FNIP1 and 
FNIP2. GST-tagged FLCN, GST-tagged FNIP1, and GST-tagged FNIP2 were over-
expressed in HEK293 cells. The cells were harvested 48 h post transfection. FLCN, 
FNIP1 and FNIP2 were purified using Glutathione Sepharose beads and then eluted 
using free glutathione. The eluent was then run on a 4-12% SDS-PAGE gel. Each 
lane was cut into 6 fractions as shown in Figure 5.10. and these fractions were 
subjected to mass spectrometry (in collaboration with Dr Bryan Balliff (University of 
Vermount)). A list of protein interactors which had at least one unique peptide hit for 
each protein is shown in Table 5.1 (FLCN interactors shown in this table are 
combined results of two independent studies). As it can be observed in Figure 5.10, 
FNIP1 is not over-expressed as well as FNIP2 or FLCN, hence not as many strong 
interactions could be detected. Some of the more prominent and more interesting 
interactors identified are as follows:  
Nuclear proteins: Component of the Nuclear Pore Complex interacting with 
FLCN such as NUP155, NUP205, NUP35, NUP188 that are part of the adaptor 
nucleoporin group, NUP160, NUP133 that are part of the coat, NUP54 that is part of 
the channel, NUP153, NUP50 and TPR that are parts of the nuclear basket, RAE1 
and RanBP2 that are parts of cytoplasmic filaments.  
In addition, other nuclear related proteins that are part of the nuclear import/export 
machinery were also found to interact with FLCN: two exportin proteins, XPO1 and 
XPO5, two importin proteins, IPO5 and IPO7, and some Histones; HIST1H1C, 
HIST1H4J, HIST2H2BE. 
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Mitochondrial proteins: a few members of the mitochondrial membrane ATP 
synthase family such as ATP5O, ATP5A1, ATP5B and ATP5C1 were found to 
interact with FLCN and ATP5F1 co-immunoprecipitated with FNIP2. ATXN10 
interacts with FLCN, which may play role in activation of mitogen-activated protein 
kinase cascade. It has also been hypothesised that ATXN10 is involved in 
maintenance of the intracellular glycosylation level and homeostasis.  
A range of translation factors and RNA related proteins: a number of 
Eukaryotic Initiation Factors including, EIF4G1, EIF4G1, EIF4G3, EIF4G3, EIF4E 
and EIF4E2 all interacting with FLCN and EIF4ENIF1 that interacts with FNIP2. 
Eukaryotic elongation factors; EEF1G and EEF1A2 were both found to interact with 
FLCN. SERPINE1 mRNA Binding Protein 1 (SERBP1) also interacting with FLCN. 
Ubiquitin related proteins: Ubiquitin-activating enzyme E1, UBA1, interacting 
with FLCN.  Ubiquitin specific peptidase 9, X-linked, USP9X, interacting with 
FLCN. UBC; RPS27A; UBB interacting with both FLCN and FNIP2. 
BAG proteins: BAG2 interacting with both FLCN and FNIP2, BAG4 and BAG5 
interacting with FLCN. BAG proteins are highly conserved chaperone regulating 
proteins. 
A cilia related protein interacting both with FLCN and FNIP1: KIAA1751 
(CFAP74), (Cilia and Flagella Associated Protein 74) which is part of the central 
apparatus of the cilium axoneme. 
Rho GTPase Activating Proteins (ARHGAP): ARHGAP5 interacting with 
FLCN and ARHGAP15 interacting with FNIP2. They convert Rho GTPases to 
inactive GDP-bound state.  
 134 
 
Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, 
Theta (YWHAQ): YWHAQ interacts with both FLCN and FNIP2. It belongs to a big 
family of activation proteins that mediates signal transduction by binding phospho-
serine/phospho-threonine proteins and is involved in cell proliferation, cell survival, 
apoptosis and stress signalling pathways.   
Apoptosis-Related Cysteine Protease, CASP7: interacting with FNIP2. 
CASP7 is an Effector caspase that interacts with and cleaves downstream 
substrates. 
Cytoskeleton Associated Protein 5, CKAP5: interacting with FLCN. CKAP5 is 
a spindle protein that is involved in mitosis. 
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Figure 5.10 GST purification of FLCN, FNIP1 and FNIP2: HEK293 cells 
expressing either GST-FLCN, GST-FNIP1 or GST-FNIP2, with non-
transfected cells as a control, were subjected to GST purification after lysis, 
with Glutathione-Sepharose. GST-tagged proteins and protein interactors 
were eluted with free Glutathione and resolved on SDS-PAGE and stained 
with Coomassie Brilliant Blue. Gel lanes were excised in strips (fraction 1-6), 
and sent to our collaborators (Dr. Brian Ballif, University of Vermont) for 
protein ID by mass-spec. 
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FLCN 
 
FNIP1 
 
FNIP2 
ANKRD44 HSPA1A;HSPA1B RAE1 ACAP2 AEBP2 KCNQ3 SUZ12 
ATP5O HSPA1L RANBP2 ARAP2 AHNAK2 LMOD2 SYNE1 
ATXN10 HSPA7 RBM39 CDC20B ARHGAP15 MAP3K7 THOC2 
BAG2 HSPA8 RBM39 DNAH7 ATP5F1 MCM4 TIAM2 
CAD KHDRBS1 RNF135 DST BAG2 MYO10 TRAF6 
CKAP5 KIF20B RPL10L FLCN BRD3 NAV3 TREH 
DCD KPNA1 RPL26L1 FNIP2 C12orf66 NCOR2 TTN 
DIAPH3 MYH9 RPL23 IL33 C19orf44 NEFM UBC;RPS27A;UBB 
DSP NUP155 RPS3 KIAA1751 CASP7 PIGM URB1 
DYNC1H1 NUP188 SERBP1 MYH9 CCAR1 PIP5K1A YWHAQ 
FASN NUP50 TPR PPFIBP1 CCDC88C PRDX3 ZFP57 
FLNA NUP160 TRIM29 PRDX3 DNAH7 RASSF8 ZNF468 
FNIP1 NUP133 USP9X RPS6KA4 DNAH8 RB1  
FNIP2 NUP205 WDR31 SHC4 EHBP1L1 RGS18  
GCN1L1 NUP153 XPO1 SLC38A4 EIF4ENIF1 RPL4  
HIST1H1C NUP54 XPO5 SPTBN5 FLCN RPL6  
HIST1H4J NUP35 YWHAQ  FNIP1 RUFY3  
HIST2H2BE OTUD3 ZNF638  HFM1 SAMD8  
HNRNPK PPP2R1A   HNRNPUL2 SP4  
HNRNPUL2 PRDX1   HSPA1A;HSPA1B STXBP5L  
HSD17B10 PRDX2   HSPA8 SUDS3  
Table 5.1 protein interactions of FLCN, FNIP1 and FNIP2 detected by mass spectrometry. 
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 NUP155 IP co-purifies FLCN, and more robustly in the presence of FNIP2  5.3.9
Unfortunately there was not enough time or resources to follow up all the 
potential protein interactions identified in the mass spectrometry analysis. 
Several members of the nuclear pore complex were shown to interact with 
FLCN, suggesting a role for FLCN in nuclear transport. NUP155 was one of the most 
prominent interacting proteins with FLCN (24 total peptide and 11 unique hits); 
hence it was selected to validate the interactions shown in mass spectrometry 
results, and to study the role of FLCN in the nuclear pore complex further.  
The nuclear pore complex is the only mode of transport for molecules over 40 
kDa in and out of the nucleus. It is composed of about 30 different proteins that are 
referred to as nucleoporins. The structure of the nuclear pore complex consists of a 
central pore, cytoplasmic filaments and nuclear basket (Hoelz et al. 2011). 
Nucleoporins are classified into 6 different categories: integral membrane 
nucleoporins (POMs) that integrate the nuclear envelope membrane, coat 
nucleoporins, adaptor nucleoporins, channel nucleoporins, nuclear basket 
nucleoporins, and cytoplasmic filament nucleoporins (Figure 5.11). 
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 Figure 5.11 Nuclear Pore Complex: A diagram of the nuclear pore complex spanning the nuclear envelope. 
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An experiment was set to study the interaction of NUP155 with wild type 
FLCN and patient derived mutants of FLCN. Over-expressed Flag-tagged NUP155 
co-purifies with HA-tagged FLCN both wild type and patient derived mutants, 
however the interaction is stronger with the patient mutants that have a truncated C-
terminus (Figure 5.12A). Since the positive effect of FNIP2 expression upon FLCN 
interaction has been observed in quite a few of the experiments so far, 
FLCN/NUP155 interaction was also tested in the presence of over-expressed Myc-
tagged FNIP2. FLCN/NUP155 interaction proved to be more robust in the presence 
of FNIP2, which was increased further with the patient mutants with a truncated C-
terminus (Figure 5.12B).   
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Figure 5.12 NUP155 IP co-purifies FLCN more robustly in the presence of FNIP2: Flag-NUP155 was co-
expressed with either wild-type FLCN, or FLCN mutant (Y463X, H429X, K508R) (A) without Myc-FNIP2 or (B) in 
the presence of Myc-FNIP2 in HEK293 cells. Anti-Flag antibody was used to immunoprecipitate Flag-NUP155 and 
associated HA-FLCN (and Myc-FNIP2, where appropriate) was determined by western blot analysis. Total protein 
expression of NUP155, FLCN and FNIP2 is shown.    
 141 
 
 FLCN IP also co-purifies NUP155, and more robustly in the presence of 5.3.10
FNIP2 
To confirm the interaction between FLCN and NUP155, a reciprocal 
experiment was setup where over-expressed HA-tagged FLCN was 
immunoprecipitated. As it is observed in Figure 5.13A the FLCN IP co-purified Flag-
tagged NUP155. Similar to the previous experiment this interaction is stronger with 
truncated patient mutants and is more robust in the presence of FNIP2 (Figure 5.13 
A,B). 
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Figure 5.13 FLCN IP also co-purifies NUP155, and more robustly in the presence of FNIP2: Flag-NUP155 was co-
expressed with either wild-type FLCN, or FLCN mutant (Y463X, H429X, K508R) (A) without Myc-FNIP2 or (B) in the 
presence of Myc-FNIP2 in HEK293 cells. Anti-HA antibody was used to immunoprecipitate HA-FLCN and associated Flag-
NUP155 (and Myc-FNIP2, where appropriate) was determined by western blot analysis. Total protein expression of 
NUP155, FLCN and FNIP2 is shown. 
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According to the mass spectrometry data (revealing the interactions), co-IPs 
and immunofluorescence (IF) co-localisation data by our collaborators (data not 
shown), figure 5.14 shows the suggested localisation of FLCN within the nuclear 
pore complex.    
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Figure 5.14 Nuclear Pore Complex and FLCN: A diagram depicting a model where FLCN is associated with 
integral components of the nuclear pore complex. 
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 HIF1α protein level is significantly higher in old FLCN knockdown cells 5.3.11
and new FNIP2 knockdown cells 
In the context of renal cell carcinoma, which is metabolically driven through 
Hypoxia Inducible Factor (HIF) activation, it is possible that loss of FLCN might lead 
to indirect dysregulation of HIF through many of these new interactions. As BHD 
patients acquire RCC late in life (The average age of onset is 50), dysregulation of 
HIF may take time to occur. To test this hypothesis, FLCN knockdown HK2 cells 
were grown in continuous culture for a year (>155 passage number) and compared 
to younger cells after selection (<10 passage number) for levels of HIF protein. It is 
clearly observed that HIF-1α level is significantly higher in the old FLCN knockdown 
cells compared to the control HK2 cells, whereas there is no significant difference 
between new FLCN knockdown cells and new control HK2 cells (Figure 5.15). 
Interestingly FNIP2 knockdown cells demonstrate the same significant increase in 
HIF-1α protein level observed in old FLCN knockdown cells (Figure 5.15).
 146 
 
Figure 5.15 HIF1α protein level is significantly higher in old FLCN 
knockdown cells and new FNIP2 knockdown cells: Old FLCN 
knockdown and control HK2 (>155 passage number) were assessed for 
HIF-1α and were compared to new FLCN knockdown and control HK2 
(<10 passage number). HIF-1α was also assessed in newly made FNIP1 
and FNIP2 knockdown cells. Densitometry was carried out to determine 
relative protein levels between samples and is graphed. N = 3, *** P < 
0.001. 
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5.4 Discussion   
Upon generating the FNIP knockdown HK2 cells, it was observed that the 
cells with FNIP1 knockdown underwent drastic morphological changes at the early 
stage, which then later normalised. This observation indicates that the cells go 
through an initial crisis phase after losing FNIP1; however the loss of FNIP1 seems 
to be compensated for after a few months. Accumulation of fatty droplets during this 
shock period places FNIP1 in metabolic pathways, specifically fatty acid oxidation 
and/or lipogenesis. However it has to be said that due to the slow growth and small 
number of the cells present at this crisis stage, they could not be tested to confirm 
the presence of fatty droplets by other means such as Oil Red O dye. Furthermore, it 
is possible that the cells went into the crisis stage as a result of other technical 
difficulties (such as clonal selection, not having the optimal proximity to each other 
etc.), not just lack of FNIP1. Although the FNIP2 knockdown cells did not 
demonstrate such extreme morphological changes, the growth was slowed and 
some minor morphological changes were also observed. The presence of spiky 
cytoplasmic projections observed in FNIP2 knockdown cells could indicate a role for 
FNIP2 in cytokinesis. Remarkably in line with these observations, in FNIP1 and 
FNIP2 knockdown mice generated by Hasumi et.al., there was no pathogenic 
phenotype observed with FNIP2 knockdown, whereas the FNIP1 mouse exhibits a 
similar phenotype to the FLCN mouse model (Hasumi et al. 2015).   
Interestingly, protein levels of FNIP1 and FLCN were significantly higher in 
FNIP2 knockdown cell lines, which could be as a result of compensatory 
mechanisms in the cells that try to overcome the loss of FNIP2. Increased protein 
expression in the cell could be due to 3 possibilities; increased gene transcription, 
increased protein translation or increased protein stability. To determine the reason 
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for this increase in protein levels, mRNA levels of each gene were also measured in 
the knockdown cell lines. In contrast to higher levels of FNIP1 protein in FNIP2 
knockdown cells, gene expression of FNIP1 was not significantly higher in FNIP2 
deficient cells. This rules out the possibility of increased transcription as the cause of 
elevated protein levels. Therefore, FNIP1 degradation could be reduced in the 
absence of FNIP2, or there may be an increase in FNIP1 mRNA translation due to 
FNIP2 loss. Conversely, FLCN gene expression, similar to its protein level, was 
significantly higher in FNIP2 knockdown cells. Hence increased transcription is 
driving a higher protein level in this case. Consequently, it could be concluded that 
FNIP2 is involved in the regulation of FLCN transcription and is also possibly 
involved in FNIP1 translation. Although protein levels of FNIP2 in FNIP knockdown 
cell lines could not be measured, gene expression of FNIP2 exhibited a significant 
increase in FNIP1-deficient cells. Since lack of FNIP1 results in increased FNIP2 
transcription, it could be possible that FNIP1 plays a role in regulating FNIP2 
transcription in a negative feedback manner where lack of FNIP1 results in higher 
FNIP2 transcription. Although more research into the FLCN/FNIP complex is 
needed, it can be speculated that FLCN/FNIP is a tightly self-regulated complex.  
FNIP1 and FNIP2 are homologous proteins with 49% identity and 74% 
similarity, indicating that they both likely share some functions within the cell, while 
each may also have additional and specific functions (Hasumi et al. 2008). Both 
FNIP1 and FNIP2 are highly conserved proteins that contain a LIR motif which 
connects them to autophagy. Generally a classic LIR motif has the protein sequence 
of (W/F/Y)XX(L/I/V). The LIR motif sequence on FNIP2 is FEYI which is a classic F-
type LIR motif that evolutionarily has a higher affinity for the GABARAP subfamily of 
Atg8s (Alemu et al. 2012). However FNIP1 only has a partial LIR motif with the 
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sequence of LEFI. This could explain the FNIP2 requirement for GABARAP/FLCN 
binding, whilst FNIP1 has less impact (shown in Chapter 3). Several attempts were 
made to insert FNIP2’s LIR motif into FNIP1 by site-directed mutagenesis, to check if 
it would enhance FLCN’s binding to GABARAP in the same manner as FNIP2. 
Unfortunately, creating the mutant was not successful which is probably due to the 
number of base changes that had to be made at once.   
Similarly to FLCN gene expression levels, expression of both FNIP1 and 
FNIP2 were significantly increased upon starvation in normal HK2 cells, further 
suggesting a role for the FNIP proteins in autophagy. FNIP2 mRNA level displayed a 
drastic increase (up to 9 fold), when the cells were depleted of nutrients; which 
together with the classic F-type LIR motif suggests a more prominent role for FNIP2 
in autophagy. Of interest, when the knockdown cell lines were studied for autophagy 
markers, GABARAP and p62, FNIP2 knockdown cells demonstrated a significant 
increase in both p62 and GABARAP protein levels, suggesting an impaired 
autophagy response in FNIP2 knockdown cells. In this context FNIP2 knockdown 
cells mimic the autophagy defects observed in FLCN knockdown cells. However 
these results on their own do not confirm autophagy defects in FNIP2 knockdown 
cells and further experiments such as autophagic flux and LC3 blots are needed to 
conclusively place FNIP2 in autophagy, which due to time restrictions could not be 
done in this study. FNIP1 knockdown cell lines did not show any significant changes 
in GABARAP or p62 protein levels, although GABARAP protein levels exhibited an 
increasing trend. Inconclusively, p62 protein levels in the FNIP1 knockdown cells 
were either higher or lower compared to control HK2 cells in different experimental 
repeats, and did not demonstrate any consistency. 
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Since FNIP1 and FNIP2 have a high degree of sequence homology, 
especially at the N-terminal and the last 158 C-terminal residues, it is speculated 
they may have similar cellular functions, which suggests that they can compensate 
for each other with these overlapping functions. Interestingly, Hasumi et.al. showed 
that only a kidney specific double knockout of FNIP1 and FNIP2 led to production of 
enlarged polycystic kidneys (Hasumi et al. 2015). Therefore, the next logical step for 
this study would be to produce a double knockdown of FNIP1 and FNIP2 to further 
analyse the effect of these two proteins in a human cell.  
In general, most of the proteins that FLCN, FNIP1 and FNIP2 interact with are 
involved in major physiological cellular processes, including apoptosis, stress 
response, cell cycle/ cell differentiation and in some cases tumourigenesis. 
NUP155 is one of the nucleoporins located in the central pore of the nuclear 
pore complex that interacts with FLCN. It was observed that the interaction of 
FLCN/NUP155 was stronger in the disease setting, i.e., presence of patient-derived 
FLCN mutants. The same result was also observed for the reciprocal experiment. 
Furthermore, in both experiments, the presence of FNIP2 made the interaction more 
robust. It could be speculated that the presence of the FLCN C-terminus is essential 
for dissociation of NUP155 from FLCN and smooth transport of FLCN in and out of 
nucleus.  
Given the multiple interactions that FLCN and the FNIPs are involved in, it 
would appear that FLCN might have a general housekeeping role in a cell, which 
when lost may lead to cancer. Also taking into account that the onset of RCC in BHD 
syndrome is >50 years of age, the effects of FLCN loss takes time to occur.  One of 
the pathways that FLCN is involved in which might be altered over time, probably 
 151 
 
due to long term production of ROS, is the HIF signalling pathway. To mimic the long 
term effects of FLCN loss in BHD patients, FLCN knockdown cells were grown in 
continuous culture for a year, resulting in increased HIF-1α protein levels compared 
with the control HK2 cells that were grown for the same length of time. Further 
investigation is required to determine whether this is a direct result of FLCN loss or 
due to sporadic mutations occurring due to long term culturing of these cells.  
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6 Chapter 6: Final discussion 
The aim of this research was to better characterise the function of FLCN and 
its associated proteins, FNIP1 and FNIP2, in cellular processes such as autophagy 
and their dysregulation in genetic diseases such as BHD.  
6.1 FLCN is a positive driver of autophagy 
 During the course of this study it was shown that FLCN interacts with and is a 
new downstream substrate of ULK1. FLCN also interacts with GABARAP and 
several Rab small G proteins linked to autophagy and these interactions were shown 
to be modulated via ULK1 phosphorylation of FLCN. Additionally it was 
demonstrated that FLCN has a positive role in the regulation of autophagy where a 
FLCN mutant lacking the ULK1-mediated C-terminal phosphorylation sites could not 
restore autophagy in FLCN-deficient cells whereas the WT-FLCN could rescue 
autophagy. Furthermore, p62 expression was shown to be increased in renal 
tumours from BHD patients compared to the normal renal tissue. However, FLCN’s 
role in autophagy does not seem to be straight forward as other studies have 
observed increased autophagy in FLCN-deficient cells. Liu et al. observed increased 
autophagy in dBHD-/- larvae with growth defects; however treating the Drosophila 
with the autophagy inhibitor, 3-Methyladenine, did not restore the normal growth 
whereas it could be rescued by nutrients (leucine in particular) (Liu et al. 2013). 
FLCN similar to VHL was shown to suppress LC3B-mediated autophagy and 
stimulate LC3C autophagic activity. FLCN knockdown in VHL-null cells caused 
considerable reduction in the accumulation of LC3C with an increase in LC3B 
(Bastola et al. 2013). Furthermore, Zhang et al. found FLCN-deficient UOK257 and 
ACHN-5968 cells were more sensitive to treatment with paclitaxel (a 
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chemotherapeutic drug that induces apoptosis) due to their enhanced autophagy 
compared to FLCN expressing cells (Zhang et al. 2013). As discussed earlier in 
chapter one, all the pathways that FLCN has been shown to be involved in seem to 
be highly cell type dependent and varied between experimental procedures.  
Previously, FLCN was linked to autophagy via GABARAP interaction 
(Behrends et al. 2010).  In this study it was shown that the FLCN/ GABARAP binding 
was enhanced in the presence of FNIP2 (and to a lesser extent FNIP1), which 
further indicates that FLCN in a complex with FNIP1 and FNIP2 functions to regulate 
autophagy. Weidberg et al. demonstrated that GABARAP subfamily members 
function downstream of autophagosome membrane elongation and maturation 
(Weidberg et al. 2010). This could also suggest the involvement of FLCN and FNIPs 
in maturation of autophagosomes. 
It was observed that FLCN interactions were markedly influenced upon direct 
ULK1 phosphorylation within the DENN domain of FLCN. Therefore ULK1 likely 
requires FLCN for efficient modulation of the autophagy machinery. The finding that 
FLCN could interact with a multitude of Rab small G proteins already involved in 
autophagy and trafficking events could suggest that FLCN’s main role in autophagy 
is to coordinate autophagic flux and vesicular trafficking through Rabs. Of interest, 
LST7, the yeast homologue of FLCN, has been shown to be essential for 
transportation of the amino acid permease, Gap1p, from the Golgi to the cell surface 
(Roberg et al. 1997). This role of trafficking between cellular compartments provides 
an evolutionary link to the proposed function of FLCN as an integral part of the 
autophagy machinery.  
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Guanine nucleotide exchange factors (GEFs) are regulators of small G 
proteins that mediate their activation. In higher eukaryotes, differentially expressed 
normal versus neoplastic (DENN) domain proteins are known to have Rab GEF 
activity and require a specific mechanism to target them to their site of action (Barr & 
Lambright 2010). The crystal structure of the C-terminal domain of FLCN revealed 
that FLCN contains a DENN domain suggesting that FLCN could have GEF activity 
towards Rabs (Nookala et al. 2012). However investigation of the GEF activity of 
FLCN in this study towards the Rabs involved in autophagy proved to be 
inconclusive. Enhanced binding to the non-guanine nucleotide binding mutants of 
Rabs is expected to be observed from a GEF, however, these Rab mutants bound 
sometimes less favourably and sometimes more favourably to FLCN. It could be 
hypothesised that FLCN, associated with different FNIP1 and FNIP2 proteins (as 
multimers), would act as a small G protein scaffold to control the direction of 
autophagosome/lysosome travel through appropriate activation of Rabs. In support 
of this, the finding that FNIP1 and FNIP2 also have DENN domains (Zhang et al. 
2012) would imply that these larger FLCN/FNIP complexes are multifunctional small 
G protein regulators. Furthermore, Tsun et al. found FLCN to be a GAP for the 
RagC/D GTPases (Tsun et al. 2013). FLCN could be considered as an atypical 
GAP/GEF protein, where the GEF domain is C-terminal and the GAP domain could 
be postulated to be found within the N-terminus. With the addition of the DENN 
domains in both FNIP1 and FNIP2, this might explain why FLCN/FNIP complexes 
can bind to a range of different small G proteins. This dual function of FLCN to be 
able to bind to the same small G protein irrespective of its GTP- or GDP-bound 
status is what makes it atypical. This dual function would explain why FLCN was 
able to bind the Rab small G proteins in both GTP- and GDP-bound states. 
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6.2 Role of FNIP1 in familial multiple discoid fibromas (FMDF) 
During the course of this study, a new patient disease incurring mutations to 
FNIP1 was discovered (FMDF), which provided a useful genetic tool to further 
characterise FNIP1’s interactions within the FLCN/FNIP complex. This is the first 
human genetic disease caused by FLCN interacting proteins, however the 
mechanism of its pathogenesis is not yet fully understood. The fact that FMDF 
patients only display skin abnormalities suggests that FNIP1 plays a critical role in 
the skin. Takagi et al. and Hasumi et al. demonstrated that FNIP2 is expressed at 
higher levels than FNIP1 in lung and kidney tissues (Takagi et al. 2008)(Hasumi et 
al. 2008) which could be the reason why loss of FNIP1 function does not cause any 
phenotype abnormalities in these organs. It is also possible that FNIP1 Val663fsX is 
expressed at higher levels in the skin and its impaired FLCN binding is causing the 
skin phenotype in FMDF patients. However, it was shown that FNIP1 Val663fsX 
retains the ability to bind FNIP2 through which the altered protein could maintain 
partial functionality. Alternatively, lack of a systemic phenotype could be explained 
by compensation through FNIP2. Since the complete deletion of FNIP1 gene was 
shown not to cause any of the FMDF symptoms, haplo-insufficienciency could be 
ruled out as the pathogenesis mechanism. Furthermore, lack of cancer within the 
FMDF patient population is good genetic evidence that loss of FNIP1 is not sufficient 
in itself to cause cancer. 
 
 
 
 
 156 
 
6.3 Characterising FNIP1 and FNIP2  
To better characterise FLCN interacting partners, FNIP1 and FNIP2, HK2 
stable knockdown cells were generated and studied. At the early stages of the 
FNIP1 knockdown the cells displayed extreme morphological changes which were 
normalised later. These results indicate that after the initial shock of FNIP1 loss the 
cells can subsequently compensate. However, lack of FNIP2 did not cause such 
initial crisis in the cell, although some minor morphological changes could still be 
observed. Of interest, Hasumi et al. reported that the FNIP1 mouse model could 
produce kidney cysts whereas a FNIP2 mouse model did not produce any 
pathogenic phenotype (Hasumi et al. 2015).  
FNIP2 knockdown caused a significant increase in FNIP1 and FLCN protein 
levels. After mRNA levels were measured, it was revealed that in contrast to an 
increased protein level, FNIP1 gene expression was not significantly increased in 
FNIP2 knockdown cells. This data suggests that FNIP2 deficiency could result in 
increased mRNA translation, or FNIP1 could become a more stable protein in the 
absence of FNIP2. However, FLCN mRNA level comparable to its protein level was 
significantly increased upon loss of FNIP2 which is suggestive of an increased 
transcription as the cause of this high level of protein. Hence it could be concluded 
that FNIP2 is involved in the regulation of FLCN transcription and it is possibly 
involved in FNIP1 translation or stability. 
Although lack of FNIP1 did not result in any significant changes in FLCN 
protein or mRNA levels, FNIP2 gene expression showed a significant increase in 
FNIP1-deficient cells. Since the transcription of FNIP2 mRNA is significantly 
increased upon loss of FNIP1, FNIP1 could be regulating FNIP2’s transcription in a 
negative feedback manner.  
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FNIP1 and FNIP2 are highly conserved proteins that both contain a LIR motif. 
The LIR consists of a short hydrophobic region with sequence of (W/F/Y)XX(L/I/V). 
LIR-containing proteins are known to be involved in selective autophagy (Alemu et 
al. 2012)(Birgisdottir et al. 2013). FNIP2’s LIR motif has the sequence of FEYI, which 
is a classic F-type LIR motif that evolutionarily has a higher affinity for the GABARAP 
subfamily of Atg8s; whereas FNIP1’s LIR motif is partial with the sequence of LEFI. 
The necessary presence of FNIP2 for the interaction of FLCN and GABARAP 
demonstrated in Chapter 3, could be as a result of this LIR motif.  
FNIP1 and FNIP 2 gene expression were found to be significantly increased 
when normal HK2 cells were starved, which further implicates the FNIP proteins in 
autophagy. Furthermore, in the FNIP2 knockdown cell lines both p62 and GABARAP 
protein levels demonstrated a significant increase suggestive of impaired autophagy. 
However, no significant changes of GABARAP or p62 protein levels were observed 
in FNIP1 knockdown cell lines.  
FNIP1 and FNIP2 have a high degree of sequence homology with 49% 
identity and 74% similarity, it is likely that have some shared functions while both 
may also have individual functions (Hasumi et al. 2008). This shared sequence 
suggests that they likely compensate for each other within their overlapping 
functions. Hasumi et al. has recently demonstrated that a kidney specific FNIP1 
knockout mouse only produced small kidney cysts while a kidney specific FNIP2 
knock out mouse did not produce any pathogenic phenotype. However, when both 
FNIP1 and FNIP2 were knocked out specifically in the kidney it caused enlarged 
polycystic kidneys (Hasumi et al. 2015). Similarly, to further study the role of both 
FNIP1 and FNIP2 in human cells it would be rational to generate a double 
knockdown of FNIP1 and FNIP2. 
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6.4 FLCN, FNIP1 and FNIP2 and the interacting partners 
Unbiased screens for protein interactors of FLCN, FNIP1 as well as FNIP2, 
implicate that FLCN and its associated FNIP proteins are involved in a wide range of 
cellular processes.  
The nuclear envelope protects and restricts access to the genetic material in 
the nucleus in eukaryotes. Nuclear pore complexes (NPCs) are large protein 
complexes within the nuclear envelope that provide a mode of transport for proteins 
and RNAs to and from the nucleus. NPCs consist of multiple nucleoporins (NUPs) 
that when fully assembled (with mass of ∼125 MDa) is one of the largest protein 
complexes within the cell (Alber et al. 2007)(Kabachinski & Schwartz 2015). FLCN 
was found to interact with a number of proteins within the nuclear pore complex. 
NUP155 is one of the nucleoporins located on the central pore of the nuclear pore 
complex which was found to interact with FLCN. NUP155 was found to associate 
more robustly with the C-terminal truncated (BHD patient-derived mutant) form of 
FLCN. Furthermore, the presence of FNIP2 made this NUP155/FLCN interaction 
stronger. The nuclear pore is the principal gateway between the nucleus and 
cytoplasm that permits highly regulated protein and mRNA transport. It is possible 
that the stronger interaction of NUP155 with FLCN in the disease setting could 
compromise active transport across the nuclear pore. It could also be speculated 
that the C-terminal of FLCN is necessary for the dissociation of FLCN from the 
NUP155 and transport of FLCN in and out of nucleus. 
The median age of BHD patients developing renal cell carcinoma is 50 years 
of age (Shuch et al. 2014). Therefore, following loss of FLCN it takes time for cancer 
to progress. FLCN has been shown to be involved in the HIF signalling pathway 
(Preston et al. 2011)(Yan et al. 2014) and long term production of ROS and 
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metabolic transformation could be one of the contributing factors to RCC in BHD 
patients. To simulate the long term effects of FLCN loss, FLCN knockdown HK2 cells 
were grown in continuous culture for a year. Western blot analysis revealed that HIF-
1α protein levels were increased in FLCN knockdown cells compared to the control 
HK2 cells that were grown for the same length of time. Further investigation is 
required to determine whether this is a direct result of FLCN loss or due to sporadic 
mutations occurring due to long term culturing of these cells.  
In general, FLCN and the FNIPs are involved in multiple interactions in the 
cell which could mean that FLCN and its interacting partners might have a more 
universal housekeeping role, which when lost may lead to cancer. 
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6.5 Future Work 
 The implication of FLCN in the autophagy pathway has provided a great tool 
to explore therapeutic targets for treating BHD patients. However autophagy can be 
a double edged sword in regard to cancer where impaired autophagy at the early 
stages can lead to cancer, while higher levels of autophagy could function as a 
survival mechanism. Therefore, the effect of both autophagy inhibitors and activators 
needs to be investigated on FLCN-deficient cell lines. 
Moreover several interesting FLCN and FNIP interactors were identified by 
mass spectrometry, which need to be further investigated to better understand the 
diverse functions of FLCN, FNIP1 and FNIP2 within the cell. 
To fully examine the role of FNIP1 and FNIP2 and to characterise their 
cellular function better, a double knockdown cell line needs to be made and 
investigated. 
The data in this thesis, combined with recent publications showing FLCN’s 
potential GAP/GEF activity implies that FLCN or most probably the FLCN/FNIP 
complex could function to regulate small G proteins within the cell and therefore co-
ordinate trafficking. This possibility needs to be further investigated. 
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